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CHAPTER I 
 
 
INTRODUCTION 
Diet and lifestyle factors continue to be the cornerstone in health and prevention of 
chronic disease. Fruit and vegetable consumption is associated with the primary 
prevention of cardiovascular disease as well as improved management of diabetes (1,2). 
Many of the health benefits associated with diets high in fruits and vegetables are 
attributed to their phytochemical content (2,3). Pomegranate fruit, high in fiber and 
antioxidant phytochemicals, exhibits a protective effect against the development of 
cardiovascular disease (4-6). However, little is known about the effects of pomegranate 
supplementation on the oxidative stress and inflammation associated with type 2 diabetes. 
Thus, there exists a need to study the effects of pomegranate polyphenol supplements on 
biomarkers of oxidative stress and inflammation in adults with type 2 diabetes versus 
healthy controls.  
 
Phytochemicals 
Phytochemicals are nonnutritive, biologically active, secondary plant metabolites that are 
currently of intense research interest due to their proposed benefits to human health (3). 
Specific health benefits are related to chronic diseases such as cancer and cardiovascular
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disease (7).  Phytochemicals provide much of the flavor and color of the edible plants and 
the beverages that are derived from them. They are not considered essential nutrients like 
proteins, fats, carbohydrates, vitamins, minerals, and water and for this reason are often 
referred to as “nonnutritive” compounds (3). 
 
Phytochemicals are found in fruits, vegetables, legumes, grains, herbs, tea and spices (8). 
They are thought to be produced by plants as a means of protection against dangers such 
as harmful ultraviolet (UV) radiation, pathogens, and herbivorous predators (3). 
Phytochemicals are also known to possess numerous structural variations. These 
variations impart unique chemical and biological properties to phytochemical classes and 
subclasses. Polyphenolic phytochemicals, which are phenolic rings bearing multiple 
hydroxyl groups, make up the largest category of phytochemicals in the plant kingdom 
(8). There are over 8,000 polyphenol compounds that may be further divided into a 
variety of classes depending on the classification system, which is based on structure.  
Flavonoids are one of the largest of these classes and can be broken down into several 
subclasses, listed in Table 1 (8,9). Although the flavonoid group includes many of the 
thousands of phytochemicals, numerous other phytochemicals are found in food. 
Examples of other phytochemicals are also listed in Table 1 (8,9). Most plant foods 
contain multiple phytochemicals. For example, the tomato may contain as many as 
10,000 different phytochemicals (8). 
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Table 1. Phytochemicals and their sources 
Phytochemical Class Phytochemicals Sources 
Flavonoids     
     Flavonols Quercetin, kaempferol, 
myricetin 
Onions, tea, olive, kale, leaf lettuce, cranberry, 
tomato, apple, turnip, green, endive, ginkgo 
biloba 
     Flavanols Catechins, epicatechins Green tea, pear, wine, apple 
 
     Flavones Apigenin, luteolin Parsley, some cereals 
 
     Flavanones Tangeritin, naringenin, 
hesperitin, hesperedin 
 
Citrus fruits 
     Anthocyanidins Cyanidin Berries, cherries, plums, red wine 
     Isoflavones Genistein, daidzein, equol Legumes, especially soybeans, nuts, milk, 
cheese, flour, tofu, miso, soy sauce 
 
Carotenoids β-carotene, α-carotene, lutein, 
lycopene 
Tomato, pumpkin, squash, carrot, watermelon, 
papaya, guava 
 
Lignans Secoisolariciresinol, 
mataresinol 
 
Berries, flaxseed/oils, nuts, rye bran 
 
Glucosinolates Glucobrassicin, gluconapin, 
sinigrin,  glucoiberin 
Cruciferous vegetables: Broccoli, cabbage, 
Brussel sprouts, mustard, watercress 
 
Isothiocyanates Allylisothiocyanates, indoles, 
sulforaphane 
 
Cruciferous vegetables (see above) 
Terpenes Limonene, carvone Citrus fruits, cherries, ginkgo biloba 
 
Phenolic Acid   
       Hydroxycinnamic 
       acids 
Caffeic, ferulic, 
chlorogenic, 
neochlorogenic, curcumin 
 
Blueberry, cherry, pear, apple, orange, 
grapefruit, white potato, coffee bean,                     
St. John's Wort, echinacea 
       Hydroxybenzoic  
       acids 
ellagic, gallic Raspberry, strawberry, grape juice 
 
Phytosterols β-sitosterol, campesterol, 
stigmasterol 
Vegetable oils (soy, rapeseed, corn, 
sunflower) 
Tannins    
    Condensed Catechin, epicatechin 
polymers 
Lentils, black-eyed peas, dark and light 
grapes, red wine, white wine, apple juice 
    Hydrolyzable  ellagic, gallic Berries, nuts 
 
Resveratrol  Grapes, red wine, purple grape juice, peanuts 
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Phytochemicals are believed to play several important roles in the body. Flavonoids are 
found in the cell membranes between the aqueous and lipid bilayers, where they exhibit 
antioxidant functions in the body by scavenging free radicals like hydroxyl, peroxyl, 
alkyl peroxyl and superoxide (8). Flavonoids can also terminate chain reactions. 
Carotenoids serve as antioxidants and are also thought to play a role in cell proliferation, 
growth and differentiation as well as enhancing cell-mediated immune responses. 
Lignans are known for their anti-estrogenic and antioxidant effects. Glucosinolates and 
isothiocyanates, as well as terpenes and phenolic acids such as hydroxycinnamic acid 
seem to have some protective effects against tumor formation associated with cancer. 
Phytosterols and isoflavones have been found to exhibit cholesterol-lowering effects, 
which may protect against heart disease. In fact, various margarines with added 
phytosterols are currently being marketed for use in the diets of people who have 
hypercholesterolemia. Tannins are high molecular weight phenolic compounds that react 
with mouth proteins to cause the taste sensation known as astringency (9). Tannins can be 
divided into two groups: condensed and hydrolysable. The condensed tannins typically 
accumulate in the outer layers of plants. The phytochemical class resveratrol has been 
associated with estrogenic and anti-esterogenic activity as well as inhibition of vascular 
smooth muscle cell proliferation.  
 
As mentioned previously, the consumption of a plant based, phytochemical rich diet has 
been associated with reduced risk of chronic illnesses including cancers, inflammation, 
cardiovascular and neurodegenerative diseases. For this reason, it is of utmost importance 
for researchers to explore the health benefits of phytochemicals in human health.  
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Diabetes, Obesity and Oxidative Damage 
Diabetes mellitus is characterized by high blood glucose as a result of impaired insulin 
secretion, action, or a combination of both (10). Insulin is a hormone produced by the β-
cells of the pancreas and is necessary for the uptake of glucose by the cells for energy. As 
a result of impaired insulin secretion, hyperglycemia occurs and can eventually cause 
long-term and short-term health complications. Such complications can include: 
dyslipidemia (high total cholesterol, and/or triglycerides or low high density lipoprotein), 
hypertension (high blood pressure), nephropathy (kidney disease), retinopathy (damage 
to the retina of the eye), and neuropathy (loss of sensation from peripheral nerve and 
vessel damage).  According to the National Diabetes Statistics for 2007, a total of 23.6 
million people—7.8% of the United States population—have diabetes (11). 
Approximately 17.9 million people are diagnosed and 5.6 million people are 
undiagnosed. 
 
Diabetes is classified as either type 1 or type 2 depending on impaired insulin production 
by the pancreas or impaired insulin utilization by cells, respectively (10). Type 1 diabetes 
involves the inability of the β-cells of the pancreas to produce insulin. Thus exogenous 
insulin is required for survival. People who suffer from type 1 diabetes tend to be lean, 
presenting significant weight loss in addition to other abrupt symptoms. Type 2 diabetes 
is the most prevalent form of diabetes, as it accounts for approximately 90% to 95% of all 
diagnosed cases of diabetes. Type 2 diabetes is associated with insulin resistance, 
regardless of the endogenous insulin level. Therefore, even if the β-cells produce a 
sufficient amount of insulin, the cells do not respond to the insulin and glucose remains in 
the blood, causing hyperglycemia. Type 2 diabetes is considered to be a progressive 
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disease and is often present for many years before it is diagnosed.  Because type 2 
diabetes develops gradually, symptoms often go unnoticed in the early stages when the 
condition could be reversed.  Family history, obesity, intra-abdominal fat, lack of 
physical activity, and race or ethnicity are some of the risk factors associated with type 2 
diabetes. 
 
The prevalence of obesity and related chronic diseases including type 2 diabetes and 
cardiovascular disease have been increasing at a rapid rate worldwide. Obesity is 
characterized by excessive accumulation of adipose tissue particularly around the 
waistline (12). This excess accumulation of adipose tissue greatly increases the risk of a 
number of metabolic disorders including dyslipidemia, insulin resistance, chronic 
inflammation, endothelial dysfunction, and hypertension. Metabolic syndrome, which is 
considered a prediabetic state, is diagnosed by increased central obesity, elevated serum 
triglycerides, reduced HDL-cholesterol, raised blood pressure or raised fasting plasma 
glucose (13). 
 
As mentioned previously, diabetes is related to impaired metabolism of glucose and 
insulin in the muscle, adipose tissue and liver, resulting in reduced sensitivity and 
secretion of insulin as well as a higher resistance to the action of insulin (12).  The 
development of obesity-related insulin resistance has been associated with oxidative 
stress and sub-clinical grade inflammation. Oxidative stress is the result of an imbalance 
between free radical formation and antioxidant status and oxidative stress has also been 
shown to stimulate inflammatory responses (14,15). It appears that hyperglycemia may 
directly contribute to the generation of oxidative stress. Hyperglycemia induces an 
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inflammatory-immune response as well as oxidative stress reactions, and generation of 
free radicals, which underlie the etiology for the complications and mortality of obesity 
and type 2 diabetes (16). 
 
A growing body of evidence supports the role of oxidative stress in the development of 
atherosclerosis (17), a major degenerative disease of the arteries, involving a series of 
inflammatory and oxidative modifications within the wall of the artery (18). The 
established risk factors for atherosclerosis include obesity, diabetes mellitus, 
hypertension, dislipidemia, smoking, aging, diets rich in saturated fat, and reduced 
physical activity (17, 19-26). Although the mechanism of the development of 
atherosclerosis is not yet fully understood, two major components appear to be  
involved (8): 
• Cells of the immune system, mainly monocytes and macrohpages (phagocytic 
cells), and T lymphocytes 
• Lipids and lipoproteins, of which LDL is the most important (oxidized or 
otherwise) 
 
A major risk factor for cardiovascular disease is high circulating levels of cholesterol (8). 
Specifically, LDL has been implicated as the prime contributor to the process, as LDL is 
the major transporter of cholesterol in the serum. Endothelial cell injury typically begins 
the initiation of the atherogenic process. Injury could be the result of mechanical stress 
such as hypertension or a high level of oxidized LDL, which is toxic to endothelial cells. 
Monocytes and T-lymphocytes adhere to the affected area at an increased rate following 
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injury, along with the infiltration of platelets. These cells are activated as a result of 
concurrent penetration of the endothelium by LDL. The platelets release growth factors, 
which stimulate the proliferation of smooth muscle cells in the arterial media. The 
smooth muscle cells collect the lipid delivered to them as LDL, which transforms them 
into lipid-laden foam cells. Monocytes or macrophages will also take up the LDL 
particles and become foam cells.   
 
Additional growth factors and chemotactic factors attract more macrophages to the site to 
create more foam cells as the macrophages are simulated by the uptake of LDL and 
release additional growth factors (8). Eventually, a plaque is formed by the proliferation 
of foam cells and smooth muscle cells. The plaque may enlarge enough to narrow the 
lumen of the artery, which restricts blood flow. The plaque cap may also rupture at some 
point or inflammatory stimuli may increase the expression of pro-coagulant tissue factor, 
which triggers thrombus formation upon the rupture of the plaque. The formation of a 
thrombus leads to acute coronary syndrome (19). Therefore, oxidative stress and 
inflammation initiate, participate in and enhance the process of atherosclerosis, and have 
been the principle targets of therapeutic interventions with dietary phytochemicals (4, 27-
33). 
 
A significant body of evidence indicates that acute hyperglycemia leads to oxidative 
stress, which is an important factor in the pathogenesis of many diabetic complications 
(34). The acute increases in blood glucose concentrations have been shown to cause an 
increase in the production of free radicals by non-enzymatic glycation and also by an 
imbalance in the ratio of NADH to NAD+ induced by the glucose in cells. Studies in both 
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healthy subjects and subjects with diabetes have provided direct evidence that induced 
hyperglycemia (35) or hyperglycemia resulting from meal intake increases blood glucose 
(35,36) and therefore can induce oxidative stress and reduce antioxidant defenses.  
 
In another study, Ceriello et al. (1999) reported that increases in oxidative stress were 
significantly greater after meals that produced a greater degree of hyperglycemia (37). Hu 
et al. (2006) reported that chronic consumption of high glycemic index foods may lead to 
chronically high oxidative stress (38). According to Dembinska-Kiec et al. (2008) the 
depletion of antioxidants and its contribution to cardiovascular complications in diabetes 
is well known (12). Many studies have found a significant decrease in plasma 
antioxidants including: α- and γ- tocopherol, β- and α- carotene, lycopene, β- 
cryptoxanthin, lutein, zeaxanthin, retinol, and also ascorbic acid in diabetes and its 
associated complications like endothelial dysfunction and atherosclerosis (39-42). The 
research supporting the therapeutic use of antioxidants for the treatment and prevention 
of complications linked to diabetes is strong (12). 
 
A high dietary intake of fruits, vegetables, and whole grains has been associated with a 
reduced risk of type 2 diabetes (1). Phytochemicals are believed to be responsible for the 
health benefits associated with a diet that is high in plant based foods.  Based on the data 
from experimental models, flavonoids, carotenoids, ascorbic acid and tocopherols are the 
major antioxidants recommended as they have demonstrated inhibition of the production 
of reactive oxygen species (43, 44). However, evidence of the potential benefits of 
polyphenols in the regulation of cellular processes including redox control and 
inflammatory responses is increasing as demonstrated in animal models and cultured 
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cells (12). Kobayashi et al. (2000) reported that tea and several plant polyphenols inhibit 
α- amylase and sucrase activity, thereby decreasing postprandial glycemia (45). Research 
has also shown that polyphenolic anthocyanins, present in berries, may prevent type 2 
diabetes and obesity (12). Results from in vitro studies suggest that anthocyanins may 
reduce the intestinal absorption of glucose by delaying the release of glucose during 
digestion.  
 
Pomegranates 
The pomegranate (Punica granatum L.) originated in the Middle East and was used 
extensively in ancient cultures for medicinal purposes for many centuries (46). 
Pomegranates adorned the vestments of the high priest in the ancient Hebrew tradition 
and the Babylonians regarded the seeds of the pomegranate as an agent of resurrection. 
The Persians believed that the pomegranate seeds conferred invincibility on the 
battlefield and the ancient Chinese believed that the seeds symbolized longevity and 
immortality.  
 
Many different types of phytochemicals have been identified from various parts of the 
pomegranate tree, fruit and seeds (3). The major class of phytochemicals present in the 
pomegranate is polyphenols. The pomegranate polyphenols include flavonoids 
(flavonols, flavanols, and anthocyanins), condensed tannins (proanthocyanidins), and 
hydrolysable tannins (ellagitannins and gallotannins). Additional phytochemicals present 
in pomegranates include organic and phenolic acids, sterols and triterpenoids, and 
alkaloids. 
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Table 2. Nutritional content of whole pomegranate (282 grams) based on samples of the 
California Wonderful ™ variety                                                                                     
The fruit is the major source of dietary pomegranate phytochemicals (3). Pomegranates 
may be consumed in a variety of ways; however, they are most popularly consumed as 
fresh fruit, in beverages (wine and juice), as food products (jams and jellies), and also as 
extracts in which they are used as botanical ingredients in herbal medicines and dietary 
supplements. The edible parts of the pomegranate fruit, which is approximately 50% of 
total fruit weight, are comprised of 80% juice and 20% seeds (6). The fresh juice contains 
85% water, 10% total sugars, and 1.5% pectin, ascorbic acid, and polyphenolic 
flavonoids.  The seeds of the pomegranate are rich in crude fibers, pectin and sugars. 
Fructose and glucose are present in similar amounts in pomegranate juice (PJ) and 50% 
of its ash content is calcium. The principle amino acids in pomegranate juice are glutamic 
and aspartic acids (6).  
 
Table 2 displays the nutritional value for a whole pomegranate (47).  The whole fruit 
weighs approximately 282 grams. Vitamin C is included in the nutritional analysis of the 
whole fruit; however, 8 oz. of pomegranate juice contains no vitamin C as vitamin C is 
very unstable and destroyed by the pasteurization process.  
 
 
 
Nutrient 
 
Unit 
1.00X1 pomegranate                    
(4” dia)---282 grams 
Energy kcal 234 
Protein g 4.71 
Fat g 3.3 
Carbohydrate g 52.7 
Fiber g 11.3 
Phosphorus mg 102 
Potassium mg 666 
Vitamin C mg 28.8 
United States Department of Agriculture. Beltsville (MD): Human Nutrition Research Center. 
c2008—[cited 2009 March 15]. Available from: http://www.nal.usda.gov/fnic/foodcomp/cgi-
bin/list_nut_edit.pl. 
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Pomegranate fruit (Punica granatum L.) is cultivated in India, Spain, Israel, and the 
United States and has been rated to contain the highest antioxidant capacity in its juice 
form, when compared to the commonly consumed polyphenols-rich beverages in the 
United States (46). Gil et al. (2000) reported the antioxidant activity of PJ to be three 
times higher than those of red wine and green tea, based on the evaluation of the free-
radical scavenging and iron-reducing capacity of the juices (48). It was also found to 
have one of the highest antioxidant capacities when compared to other fruit juices, such 
as grape, cranberry, grapefruit, blueberry or orange juice (3,49,50). Pomegranate juice 
contains approximately 5 mmol/L of total polyphenols in comparison to other fruit juices 
which contain approximately 1.3 to 4.0 mmol/L of total polyphenols (3). 
 
Ellagitannins and anthocyanins are the principal antioxidant polyphenols in PJ (48). 
Anthocyanins, which are the water-soluble pigments that give pomegranate juice its 
bright red color, are found in the arils of the pomegranate (3). The ellagitannins are 
present in the peel, the membranes and piths of the fruit and account for approximately 
92 % of the total antioxidant activity of pomegranate juice (3,48). The major 
ellagitannins present in the whole fruit are punicalagins, which can be hydrolyzed to 
ellagic acid (EA) and other smaller polyphenols in vivo (51). Commercial PJ obtained by 
pressing whole pomegranate fruit and its peels contains significant amounts of water-
soluble compounds, including punicalagins. However punicalagin levels vary widely in 
PJ and can range from as low as 0.017 to 1.5 g/L of juice depending on the fruit cultivar 
as well as the processing and storage conditions (48,52). 
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 Phytochemicals are proposed to have health benefits related to the prevention of chronic 
diseases such as cancer and cardiovascular disease (7). Recently research has focused on 
the role of antioxidant polyphenols present in the pomegranate, as pomegranate juice has 
one of the highest antioxidant capacities when compared to other fruit juices (3,49,50). 
Clinical trials thus far have focused on the role of pomegranate polyphenols in the 
oxidative stress associated with cardiovascular disease complications (4-6). However, 
research is now beginning to examine the effect of pomegranate supplementation on 
diabetic parameters as well (53).  
 
Thus the objective of our study was to examine the effects of pomegranate polyphenol 
supplementation, in the form of a POMx™ capsule, on clinical variables (fasting blood 
glucose, blood pressure, and dyslipidemia [high TCs and/or high TGs or low HDL 
levels]) and on biomarkers of oxidative stress (oxidized LDL [ox-LDL] and 
malondialdehyde [MDA] and 4-hydroxynonenal [HNE]) and inflammation (C-reactive 
protein [CRP]) in subjects with abdominal adiposity and type 2 diabetes versus healthy 
controls. 
The null hypotheses were that: 
• Pomegranate polyphenol supplementation will not affect glucose, lipids, and 
biomarkers of oxidative stress and inflammation in subjects with type 2 diabetes 
and healthy controls. 
• Pomegranate polyphenol supplementation will not affect safety parameters, such 
as, liver, kidney, and thyroid function tests, and complete blood cell count, in 
subjects with type 2 diabetes and healthy controls. 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
The pomegranate (Punica granatum L.), high in a variety of polyphenolic 
phytochemicals, has been found to exert anti-atherosclerotic, anti-hypertensive, and anti-
oxidative properties in both human and animal studies (4-6). However, much of the 
research with pomegranates thus far has been conducted in the Middle East with 
pomegranate juice and limited research has been conducted in human subjects with type 
2 diabetes. Type 2 diabetes is associated with oxidative stress and sub-clinical grade 
inflammation, thus warranting the need to further investigate the effects of pomegranate 
polyphenols in subjects with type 2 diabetes, which is the scope of our study.  
 
Pomegranate Juice Clinical Trials  
A two week clinical trial was conducted among ten hypertensive, non-smoking patients 
who were supplemented with PJ (50 ml containing 1.5 mmol total polyphenols per day, 
for two weeks) (5). The aim of this clinical trial was to determine the effect of PJ, which 
possesses anti-oxidative properties, on blood pressure and on angiotensin converting 
enzyme (ACE). Participants were all between the age of 62 and 77 years and had a mean 
blood pressure of 155 ± 7/83 ± 7 mmHg at baseline. Two participants were diabetic 
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(serum glucose >126 mg/dl) and two were hyperlipidemic (serum cholesterol >240 
mg/dl). Adherence to protocol was confirmed by serum total polyphenols analysis.  
Researchers also studied the in vitro effects of PJ on serum ACE activity. 
 
In seven of the ten hypertensive patients, ACE activity was significantly decreased by 
36% after two weeks PJ consumption (5). The inhibitory effects of PJ consumption on 
serum ACE activity may be secondary to the antioxidant properties of PJ or a result of the 
direct effect of the juice’s active compounds on serum ACE activity. The possible direct 
effect of PJ on serum ACE activity was assessed by adding increasing concentrations of 
PJ to human serum, which was subsequently incubated for 15 minutes at 37 ºC. 
Pomegranate juice exhibited a dose-dependent inhibitory effect of up to 31% on serum 
ACE activity. This effect could be secondary to the ability of antioxidants associated with 
PJ, such as complexed tannins, to inhibit ACE activity. The inhibitory effect of PJ 
consumption on serum ACE activity may also have been the outcome of a direct 
interaction of PJ constituent with the serum ACE.   
 
Pomegranate juice was also found to have an effect on blood pressure, as there was a 
minimal (5%), but a significant (p < 0.05) reduction in systolic blood pressure (5). After 
two weeks of PJ consumption, mean blood pressure was 147 ± 10/82 ± 5 mmHg. These 
results suggest a significant inhibitory effect of PJ on serum ACE activity and a minor 
attenuation in blood pressure in hypertensive patients, which suggests that PJ 
consumption can offer protection against hypertension, a risk factor for cardiovascular 
disease. 
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Rosenblat et al. (53) investigated the effects of PJ consumption on parameters of 
oxidative stress in diabetic patients. Ten healthy male subjects (controls) and 10 non-
insulin dependent diabetes mellitus (NIDDM) patients between the ages of 35-71 years 
were recruited for this study. The controls were non-smokers, history without diabetes 
(glucose levels below 100 mg/dL and hemoglobin A1c levels in the range of 4.8-6.2%), 
hypertension or coronary artery disease, and not on any medications. The duration of 
diabetes mellitus in the patients ranged from 4-10 years. Patients with diabetes mellitus 
had glucose levels above 160 mg% and hemoglobin A1c levels between 7.5-11.3%. None 
of the patients presented ischemic heart disease or hypercholesterolemia and none were 
smokers. However, 50% of the patients were hypertriglyceridemic with serum 
triglyceride levels ranging from 300-790 mg%. Glucophage (Metformin) was used for 
treatment in 80% of the patients and (Glybenclamid) Gluben was used by 50%.  
 
The patients consumed 50 ml of pomegranate juice (containing 1.5 mmol of total 
polyphenols) for a three month period (53). Blood samples were collected from the 
diabetic patients and the controls before and after three months of PJ consumption for 
analysis of biochemical parameters. Also, blood samples from two healthy controls and 
three diabetic patients before and after PJ consumption were used for preparation of 
monocytes-derived macrophages.  
 
Neither serum glucose, cholesterol, nor triglyceride levels appeared to be affected by 
consumption of PJ (53). The patients had higher levels of lipid peroxides (by 350%) and 
TBARS (by 51%) when compared to the controls. However, serum sulfhydryl (SH) 
group content was as much as 21% lower in patients versus the controls and paraoxonase- 
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1 (PON1) arylesterase activity was 23% lower. The consumption of PJ resulted in a 
significant reduction in serum lipid peroxides and TBARS levels by 56% and 28%, while 
serum SH groups and PON1arylesterase activity significantly increased by 12% and 24%, 
respectively.  
 
The human monocytes-derived macrophages (HMDM) of the diabetic patients were 
observed to have an increased level of cellular peroxides (by 36%) and a decreased level 
of glutathione (by 64%) when compared to the healthy controls (53). Consumption of PJ 
significantly decreased cellular peroxides by as much as 71%, and increased glutathione 
levels by 141% in the patients’ HMDM. Furthermore, the HMDM of the patients 
compared to the controls took up oxidized LDL (ox-LDL) at an enhanced rate by 37% 
and PJ consumption decreased the extent of ox-LDL cellular uptake significantly (by 
39%). These results indicated that PJ consumption did not worsen diabetic parameters in 
the patients, and instead resulted in anti-oxidative effects on both serum and 
macrophages, which could likely contribute to attenuation of atherosclerosis development 
in patients with NIDDM.  
 
The effects PJ on LDL atherogenic modifications including its retention, oxidation, and 
aggregation were examined in healthy male subjects (6). Two ex vivo studies were 
performed to determine the antioxidant effect of PJ. In the first study, 13 healthy men 
aged 20-35 years were supplemented with 50 ml PJ/d (1.5 mmol total polyphenols) for 
two weeks. In the second study, three subjects were given increasing doses of PJ (20-80 
mL/d, equivalent to 0.54-2.16 mmol total polyphenols/d). Results from the ex vivo 
human studies showed that after two weeks of PJ supplementation there was a small but 
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significant (6%; p < 0.01) decrease in susceptibility to 2,2-azobis-2-amidinopropane 
hydrochloride (AAPH)-induced lipid peroxidation compared with plasma obtained prior 
to study entry. Also, a significant (9%; p < 0.05) increase was observed in plasma total 
antioxidant status after two week consumption of PJ. Three subjects were studied further, 
in order to determine the effects of varying doses of PJ on AAPH-induced plasma lipid 
peroxidation and to analyze the ability of PJ to maintain its effect after consumption of 
the juice had stopped. The results indicated the inhibitory effect of PJ intake on plasma 
lipid peroxidation was maintained for two weeks after the PJ supplementation was 
discontinued.  
 
After two weeks of PJ consumption, there was a significant (18%: p<0.01) increase in 
serum paraoxonase (6). Due to the fact that serum paraoxonase is bound to HDL, the 
researchers questioned whether increased serum paraoxonase activity would be 
associated with increased resistance of HDL to oxidation after PJ supplementation. PJ 
consumption was found to gradually and significantly (p < 0.01) increase the resistance 
of HDL to copper ion-induced oxidation. HDL-associated paraoxonase activity in serum 
is linked with the protection of LDL from oxidation. When human serum was incubated 
with increasing concentrations of PJ for 10 minutes at 37˚C, PJ exerted a dose dependent 
increase in serum paraoxonase activity by up to 33%. Such results suggest that PJ inhibits 
plasma LDL lipid peroxidation in vitro and that this effect is related to its capacity to 
scavenge free radicals and to also increase serum paraoxonase activity.  
 
Furthermore, the susceptibility of LDL to copper-ion induced oxidation was also 
gradually reduced with consumption of PJ (6). A pattern of reduction in LDL aggregation 
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was observed in 7 of the 13 subjects; however, the mean value did not change 
significantly.  
 
The effect of PJ on human platelet aggregation was assessed in vitro and ex vivo (6). 
Platelet-rich plasma was incubated with increasing concentrations of PJ and aggregation 
was induced by adding collagen. The PJ inhibited collagen-induced platelet aggregation 
by as much as 90% in a dose dependent manner. In the ex vivo study, collagen-induced 
platelet aggregation was significantly reduced by 11% (p < 0.02) compared with platelet 
aggregation before PJ consumption. Based on the results it was concluded that the 
antiatherogenic properties of PJ are related to its ability to inhibit lipid peroxidation in 
plasma and lipoproteins. Thus PJ appears to have potent antiatherogenic effects in 
healthy humans that may be attributable to its antioxidative properties.  
 
Pomegranate juice consumption has become increasingly popular due to its reported 
benefits on human health (54). Thus research with pomegranates has focused on the 
effects of PJ on biomarkers of oxidative stress and inflammation. However, pomegranate 
extracts, which contain the major antioxidants present in pomegranates, have been 
developed as a botanical dietary supplement to offer a convenient alternative to 
consuming the bioactive polyphenols in juice form. Despite the fact that pomegranate 
supplements are commercially available, few studies have analyzed them for their safety 
and potential benefits to human health. Heber et al. (2007) was the first to analyze the 
safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol extract 
20 
 
(POMx™) in overweight individuals with increased waist size in two pilot studies to 
demonstrate both the safety and efficacy of POMx™ in humans. 
  
In the first study, the safety of POMx™ was determined in overweight subjects (54). The 
subjects were instructed to consume either one or two POMx™ capsules per day (1 
capsule = 710 mg extract with 435 mg gallic acid equivalents [GAEs]; 2 capsules = 1420 
mg extract with 870 mg GAEs). In order to maintain blinding, the one capsule per day 
group received one bottle of placebo and one bottle of POMx™ capsules. Participants in 
the two capsules per day group received two bottles of POMx™ capsules. Additionally, 7 
of the 64 subjects received only one placebo during the trial to assess the incidence of 
adverse effects in the group receiving only the placebo. In this study, there was a formal 
assessment of adverse reactions and a comprehensive series of blood tests for toxicity by 
comparison to the control group that received a placebo. None of the subjects 
discontinued the study as the results of an adverse event and no serious adverse events 
were reported. Of the adverse events reported none were believed to be related to the 
supplement. Also, there were no apparent treatment-related changes of clinical 
significance and no laboratory values were outside the normal range in any of the 
chemistry, hematology, or urinalysis parameters.  
 
In the second study, subjects consumed two POMx™ capsules daily, which provided 
1000 mg of extract containing 610 mg of GAEs, in order to determine the antioxidant 
activity of the supplements (54). Subjects were instructed to avoid foods with strong 
antioxidant properties for the duration of the trial. Thiobarbituric acid reactive substances 
21 
 
(TBARS) in plasma were measured before and after POMx™ supplementation as a 
marker of antioxidant activity. There was a significant decrease (p = 0.044) in TBARS 
between baseline and four weeks. No significant differences were detected for glucose, 
BUN, creatinine, lipids, c-peptide, paraoxonase-1, or electrolytes or liver enzymes 
(aspartate amino transferase [AST] or alanine amino transferase [ALT]).  
 
Thus these pilot studies demonstrate that a pomegranate ellagitannin-enriched polyphenol 
(POMx™) dietary supplement is safe for healthy human subjects in amounts up to 1420 
mg/day to provide 870 mg of GAEs/day for a duration of 28 days (53). However, future 
studies with POMx™ capsules are needed to confirm these results as well as the effects 
of the POMx™ capsules in patients with chronic diseases such as type 2 diabetes.  
 
Epidemiological Findings 
Although observational data on pomegranate intake is lacking, several epidemiological 
studies have examined the effect of dietary patterns that are high in fruit and vegetable 
intake on mortality from a variety of health outcomes including obesity, hypertension and 
cardiovascular diseases (1,2). Such studies have found that increased consumption of 
fruits and vegetables may exert beneficial effects as a result of the antioxidants and other 
phytochemicals present in these food groups (2).   
 
Bazzano et al. (2008) examined the association between fruit, vegetable, and fruit juice 
intake and the development of type 2 diabetes (1). This was a large prospective cohort 
study that included 71,346 female registered nurses between the ages of 38-63 years who 
did not have cardiovascular disease, cancer, or diabetes in 1984. The participants were 
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followed for a total of 18 years. A semi-quantitative food frequency questionnaire was 
administered every four years to obtain dietary information. Data on body mass index 
(BMI), physical activity, smoking status and other lifestyle factors was also collected. 
The diagnosis of diabetes was self-reported by the participants.  
 
The results of this study indicate that the women with higher intakes of fruits and 
vegetables were older, less likely to smoke cigarettes, more likely to exercise on a regular 
basis and were also more likely to use hormone replacement therapy than those women 
who did not consume fruits and vegetables as frequently (1). Approximately 4,529 cases 
of type 2 diabetes were documented over the 18 year time frame.  
 
An increase of three servings per day in total fruit and vegetable intake was not 
associated with the development of diabetes based on the multivariate-adjusted hazard 
ratio of 0.99 [95% CI 0.94-1.05] (1). An increase to three servings per day for whole fruit 
consumption was associated with a lower hazard of diabetes 0.82 [0.72-0.94]. A modestly 
lower hazard of diabetes (0.91 [0.84-0.98]) was associated with an increase of one 
serving per day of green leafy vegetables, while an increase of one serving per day in 
fruit juice intake was associated with an increased hazard of diabetes (1.18 [1.10-1.26]). 
These results suggest overall fruit and vegetable intake was not associated with the 
development of type 2 diabetes. However, there was a positive association between 
intake of fruit juices and incidence of type 2 diabetes, while intake of whole fruits and 
green leafy vegetables was inversely associated.  
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The positive association between the consumption of fruit juice and diabetes risk is 
related to the lack of fiber and other phytochemicals in juice, as well as the high sugar 
load (1). An important mechanism by which fruit juices could possibly contribute to the 
development of diabetes is related to the fast delivery of concentrated sugar without the 
components that are part of the whole fruit. The authors report that the observed 
associations between fruits and vegetables and diabetes in their study are weaker than 
those for cardiovascular disease. Yet if fruits and vegetables replace refined grains and 
white potatoes, which are associated with the increased risk of developing diabetes, the 
benefits of consuming fruits and vegetables regularly could be considerable.  
 
In a cross-sectional study, the association of fruit and vegetable intake with blood C-
reactive protein (CRP) concentrations and the prevalence of metabolic syndrome among 
female teachers between the ages of 40 and 60 years was assessed (2). All participants 
with a history of cardiovascular disease, diabetes, cancer, or stroke were excluded due to 
possible changes in diet associated with such conditions. Other exclusions included 
subjects who left > 70 items blank of the food-frequency questionnaire (FFQ), who 
reported a total daily energy intake outside the range of 800-4200kcal, and also subjects 
who were taking medications that would affect serum lipoprotein, blood pressure, and 
carbohydrate metabolism. Such exclusions resulted in a total 486 subjects eligible for 
participation. A validated 168-item semiquantitative FFQ was used to assess the usual 
dietary intake.  Assessment parameters included weight, height, body mass index (BMI), 
waist circumference, blood samples, blood pressure, and physical activity. The mean 
daily intakes of fruit and vegetables were reported as 228 ±79 and 186 ± 88 g/d, 
respectively.  
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Participants in the highest quintile of fruit and vegetable intake were more physically 
active, less likely to be obese, and had lower anthropometric measures and lower 
prevalence of metabolic syndrome (2). In this study, higher intakes of fruit and 
vegetables were associated with an overall healthier diet; subjects with high fruit and 
vegetable intake also consumed less cholesterol, meat, and refined grains and more 
dietary fiber and whole grains.  Fruit and vegetable intakes were both inversely associated 
with plasma CRP concentrations.  After statistical control was performed for age, BMI, 
and waist circumference, the mean plasma CRP concentrations across increasing quintile 
categories for fruit were 1.94, 1.79, 1.65, 1.61, and 1.56 mg/L (P for trend < 0.01) and of 
vegetables were 2.03, 1.82, 1.58, 1.52, and 1.47 mg/L (P for trend < 0.01).  After 
controlling for any potential confounders, it was determined that those subjects in the 
highest quintile of fruit intake had a 34% lower and those in the highest quintile of 
vegetable intake had a 30% lower risk of having metabolic syndrome.   
 
The results suggested that higher intakes of fruits and vegetables were associated with a 
lower risk of metabolic syndrome, and that the lower risk may be attributed to lower CRP 
concentrations (2).  Such results provide additional evidence for the hypothesis that a 
high intake of fruits and vegetables is associated with reduced plasma concentrations of 
inflammatory markers. The beneficial effect of fruits and vegetables may be related to a 
combination of antioxidants, fiber, potassium, magnesium, and other phytochemicals. 
Thus, the findings from this study are in confirmation with those of other studies which 
have shown protective effects of fruit and vegetable intake against mortality, 
cardiovascular disease, and diabetes. 
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The phytochemicals present in PJ and in fruits and vegetables have shown significant 
anti-atherosclerotic, anti-hypertensive, and anti-inflammatory effects in human subjects 
(1-2,5-6,53-54). Pomegranate juice appears to exhibit anti-oxidant effects on both serum 
and macrophages, which could likely contribute to attenuation of atherosclerosis 
development in patients with NIDDM (53). Pomegranate juice also demonstrated a dose-
dependent inhibitory effect on serum ACE activity, which is believed to result from 
ability of antioxidants associated with PJ to inhibit ACE activity (5). The recent research 
on pomegranate polyphenols and prevention of oxidative stress is promising. However, 
additional research on pomegranate polyphenol supplementation in patients with type 2 
diabetes is necessary to strengthen support for its cardio-protective effects. 
 
Mechanistic Studies 
Due to its potent antioxidant capacity and potential to improve chronic disease states 
associated with oxidative stress and inflammation the pomegranate has become of intense 
research interest. In mechanistic studies, PJ demonstrates potent anti-oxidative, anti-
atherosclerotic, and anti-hypertensive effects indicating a potential role for pomegranate 
polyphenols in reducing the risk of cardiovascular disease (4,6). 
 
Previous studies in both humans and animals afflicted with atherosclerosis indicate that 
regular administration of PJ produces a significant protective effect (4).  These positive 
effects have been extended to mice treated with pomegranate fruit extract (PFE). 
Pomegranate fruit extract, like PJ, is rich in polyphenolic antioxidants that are known to 
be potent against low density lipoprotein (LDL) oxidation and atherosclerosis. In fact, the 
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polyphenols present in PFE have the ability to reduce the expression of oxidation-
sensitive genes at the sites of perturbed shear-stress. Metabolic syndrome, which includes 
diabetes, dislipidemia, hypertension, and obesity, has become a clinically widespread 
condition associated with oxidative stress.  
 
De Nigris et al. (2007) conducted a study to compare the influence of PFE to PJ and seed 
oil on the biological actions of nitric oxide (NO) and arterial function in obese Zucker 
rats, an animal model of metabolic syndrome (4). The rats were matched for blood 
pressure and serum cholesterol and received an atherogenic diet (ATH), or an ATH diet 
supplemented with regular PJ (ATH + PJ), pomegranate fruit extract (ATH + PFE), or 
seed oil (ATH + seed oil).  
 
Acetylcholine (Ach)-induced relaxation responses were significantly increased by 
supplementation of PJ and PFE (p < 0.01) and also by seed oil supplementation (p < 
0.05), but, to a lesser extent (4). The lipid profile was found to be similar among all 
groups in that PFE supplementation had no significant effect on total cholesterol and 
LDL cholesterol. However, data did indicate that supplementation with either PFE or PJ 
significantly reduced both thrombospondin (TSP-1) and cytokine TGFβ1 expression (p < 
0.05), while seed oil supplementation only had a significant effect on expression of TSP-
1 (p < 0.05). Interestingly, the effect of PFE was comparable to that of PJ in increasing 
vascular endothelial NO synthase (eNOS) expression. PJ and PFE supplementation also 
significantly increased plasma NOx levels (p < 0.05), whereas the seed oil 
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supplementation produced no effect. Analysis of plasma insulin and glucose levels did 
not reveal any significant differences.  
 
These results demonstrate that beneficial effects related to vascular function and 
inflammation in obese Zucker rats can be achieved when an atherogenic diet is 
supplemented with PFE. Pomegranate fruit extract is expected to possess beneficial 
effects similar to those exerted by PJ as a result of its high content of polyphenolic 
antioxidants. The chronic administration of PJ, and more recently of PFE, has been 
shown to minimize the proatherogenic effects induced by perturbed shear-stress. This 
study provides evidence that PFE supplementation may positively affect arterial 
reactivity, vascular expression of eNOS and NOx levels by increasing NO production and 
preventing its degradation. Thus these data suggest potential clinical applications in 
patients with metabolic syndrome.  
 
The effect of pomegranate juice on NO has become a topic of interest because when NO 
is exposed to oxidative stress, rapid destruction occurs (50). This rapid destruction is 
typically associated with the initiation and development of a variety of cardiovascular 
diseases.  Nitric oxide is known to be a potent inhibitor of oxidative stress and 
inflammation as a result of its ability to react with and subsequently remove certain 
reactive oxygen species. If endothelial NO levels are decreased there is further oxidation 
and destruction of NO. This cycle of oxidative stress and reduced NO action can lead to 
atherosclerosis.   
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Pomegranate juice is known to be a rich source of antioxidants, thus Ignarro et al. (2006) 
conducted a study to compare PJ with other products (concord grape juice, red wine, 
white wine, blueberry juice, alcohol, vitamin C and vitamin E) that are commonly 
promoted as having antioxidant properties to determine their protective effects on NO 
when subjected to conditions of oxidative stress (50). For this study, a 
chemiluminescence headspace assay was developed to measure the antioxidant activity 
by monitoring the destruction or disappearance of NO when exposed to superoxide 
anions generated by pyrogallol. The results indicated that the inclusion of PJ clearly 
protected against the pyrogallol-elicited disappearance of NO. Pomegranate juice 
produced significant anti-oxidative activity with concentrations ranging from as little as 3 
to 100 µl of 30-fold dilution of PJ concentrate. 
 
Of the other juices tested, blueberry juice displayed appreciable antioxidant activity in the 
system observed (50). Yet the quantity required to produce the significant antioxidant 
activity (300 µl of undiluted juice) was greater than that required with PJ. Thus, PJ was 
determined to be more potent than blueberry juice in protecting NO from oxidative 
destruction as determined by this particular assay. Of the other juices tested at quantities 
of 300 µl, only the Concord grape juice and red wine exhibited significant antioxidant 
activity.  
 
In the second experiment, PJ was studied to determine its ability to enhance the 
biological activity of NO (50). When PJ was added to cell cultures there was a noticeable 
increase in the proliferative action of NO in rat aortic smooth muscle cells (RASMC). 
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Pomegranate juice alone, in absence of NO, produced no effect on cell proliferation at 
concentrations ranging from 3 to 100 µl. Such results indicate the marked protective 
effect of PJ on the anti-proliferative action of NO in the cell medium. Of the other juices 
tested, the grape juice showed significant augmentation of the anti-proliferative action of 
NO, but only at the highest concentration tested (100 µl). The blueberry juice was 
effective at 30 and 100 µl; however, the effects were only approximately 50% of the 
effect of PJ.  
 
Additionally, PJ was analyzed for its affect on endothelial NO synthase (eNOS) protein 
expression, eNOS catalytic activity, and eNOS gene promoter activity (50). It was 
determined that PJ did not have appreciable influence on eNOS protein expression in 
bovine pulmonary artery endothelial cells (BPAEC) based on results of the Western blot 
analysis.  
 
The results indicated that the antioxidants present in PJ are capable of protecting NO 
against superoxide anion mediated destruction, and also has the ability to augment certain 
biological actions of NO including inhibition of vascular smooth muscle cell proliferation 
(50). Thus the authors conclude that PJ is rich in potent antioxidants that are associated 
with anti-atherosclerotic effects in both animals and humans.  
 
In a study conducted by Aviram et al. (2001) atherosclerotic apolipoprotein E-deficient 
(E0) mice were analyzed to determine the effect of PJ consumption on lipoprotein 
oxidation, aggregation and retention; macrophage atherogenicity; platelet aggregation; 
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and atherosclerosis. Thirty, six week old E0 mice were divided in to three groups of 10 
for this study (6). The three groups were given 0, 6.25, or 12.5 µL PJ (equivalent to 0, 
0.175, and 0.350 µmol total polyphenols) in their drinking water per mouse per day. 
Blood was drawn at 6, 9, and 14 weeks of age for the plasma and LDL analysis and 
peritoneal macrophages and aortas were obtained at the end of the study. In order to 
evaluate the effect of PJ supplementation on atherosclerotic lesion progression, three 
week old E0 mice were supplemented for 11 weeks with 31 µL PJ (equivalent to 0.875 
µmol total polyphenols) per mouse per day. Control mice received only water.  
 
PJ supplementation was found to have antioxidant effects when administered to E0 mice.  
Plasma lipid peroxidation was markedly lower in mice that were fed PJ (6). A 
concentration dependent relationship was determined for this effect. Additionally, serum 
total antioxidant status was higher in the E0 mice that consumed PJ than in the control 
mice. This effect was also concentration dependent. Susceptibility of LDL from E0 mice 
to copper ion-induced oxidation was also reduced and the susceptibility of LDL to 
oxidation associated with the progressive increase in age was significantly attenuated by 
PJ consumption.  
 
Due to the fact that LDL oxidation by the macrophages is thought to be a major event in 
the initial development of atherosclerosis and is associated with cellular uptake of 
modified lipoproteins, which ultimately contributes to macrophage accumulation and 
foam cell formation, macrophage atherogenicity was examined in the E0 mice (6). Lipid 
peroxidation of the mouse peritoneal macrophages (MPMs) after supplementation with 
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PJ was 53% less than lipid peroxidation of MPMs isolated from the control mice. The 
atherosclerotic lesions in the control mice were found to be larger than those in the mice 
treated with PJ and the control mice had many more lipid-laden macrophage foam cells.  
 
This study showed the antiatherogenic properties of PJ as related to its inhibitory effect 
on lipid peroxidation in plasma, in lipoproteins, and in macrophages. Also of great 
importance, PJ treatment significantly inhibited the progression of atherosclerotic lesions. 
Thus PJ has several antiatherogenic capabilities related to its potent antioxidant capacity 
against lipid peroxidation, which is believed to be the central link for PJs effects on 
lipoproteins and macrophages.  
 
Research in animal models of obesity and atherosclerosis show the potential for 
beneficial cardio-protective health effects with administration of PJ or PFE (4,6,50). 
Epidemiological studies emphasize the importance of consumption of fruits and 
vegetables known for the phytochemical content and clinical studies have examined the 
effects of the antioxidant polyphenols present in PJ. However, initial clinical trials have 
focused on the role of pomegranate polyphenols on the oxidative stress and inflammation 
associated with cardiovascular disease. 
 
Relevance of Present Study 
Phytochemicals are currently of intense research interest due to their proposed benefits to 
human health. The pomegranate, rich in potent antioxidant polyphenols, is believed to 
inhibit the oxidative stress and inflammation that contributes to a variety of chronic 
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disease states. However, most research with pomegranates examines the effects of PJ on 
biomarkers of oxidative stress, inflammation, and atherogenic modifications. Few studies 
have examined the effects of pomegranate polyphenol capsules and the available studies 
have been conducted with overweight individuals who were otherwise healthy and free of 
chronic disease. Thus the present pilot study was conducted to determine the effects of 
pomegranate polyphenol supplementation, in the form of a POMx™ capsule, on safety 
parameters as well as biomarkers of oxidative stress and inflammation in adults with 
abdominal adiposity and type 2 diabetes versus healthy controls.  
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CHAPTER III 
 
 
METHODOLOGY 
Institutional Review Board Approval 
The pomegranate supplementation study was designed as a four week clinical trial that 
was conducted to examine the effects of pomegranate polyphenol supplementation, in the 
form of a POMx™ capsule, on biomarkers of oxidative stress and inflammation 
associated with type 2 diabetes. This study was conducted according to the guidelines 
presented in the Declaration of Helsinki and approval was obtained from the Oklahoma 
State University Institutional Review Board (IRB) for all procedures. Prior to 
involvement in the study, all investigators and graduate research assistants (GRA) 
completed the IRB training for human subjects research practices through the 
Collaborative Institutional Training Initiative (CITI) and also received training on the 
process of consenting and explaining the study, as well as subject follow-up and data 
collection. All participants provided a signed informed consent before their enrollment in 
the study. 
 
Subjects 
Subjects were recruited at the Oklahoma State University campus. Flyers were posted at 
the Department of Nutritional Sciences and the Seretean Wellness Center. 
Advertisements were also sent through e-mail as well as posted on the Oklahoma 
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State University Headlines page and the College of Human and Environmental Sciences 
homepage. Telephone questionnaires were used for the initial screening purposes and all 
potential participants were scheduled for a screening visit at the Clinical Assessment Unit 
at the Department of Nutritional Sciences (NSCI), Oklahoma State University, to ensure 
that they met study inclusion criteria.  
 
This study required participation of subjects with diabetes as well as healthy controls. 
Adults over the age of twenty-one years were recruited for both study groups.  
Inclusion criteria: Participants in the diabetic group were required to meet the following 
criteria for study inclusion: abdominal adiposity (waist circumference > 35 inches in 
women and > 40 inches in men), diabetes mellitus, stable on medications, normal 
hemoglobin (Hb), white blood cells (WBC), platelet count, and liver, kidney, and thyroid 
function tests. In order to be included in the study, healthy controls had to present a waist 
measurement of < 35 inches for women and < 40 inches for men and be free of any 
chronic disease such as diabetes, cancer, or any form of cardiovascular disease. Subjects 
were included if they were on stable medications.  
 
Exclusion criteria: Individuals were excluded if they had any form of pre-existing 
disease including cancer, heart disease, liver or renal disorders, or anemia. Subjects were 
also excluded if they were pregnant, nursing, taking mega doses of antioxidants/fish oil 
supplements (> 1g/day), had an abnormal Hb (normal range: 4.0-11.0 K/mm3), WBC 
(normal range: 12.0-18.0 g/dL), or platelets (normal range: 140-440 K/mm3), abnormal 
liver enzymes (normal range for AST: 7-40 units/L; ALT: 10-45 units/L). Individuals 
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who smoke or used any other form of tobacco were excluded as well as those who 
consumed > 1 oz. of alcohol per day.  
 
The initial screening visit consisted of a blood draw and blood pressure, waist 
circumference, weight and height measurements. Prior to the blood draws and 
measurements participants were informed of the purpose of the study, the procedures and 
any risks or potential benefits associated with the study. Participants also read and signed 
the informed consent participation agreement before anthropometric and blood pressure 
measurements and blood draws were conducted. If participants were unable to read the 
informed consent, the GRAs would read the consent to the participant. Based on the 
initial screening results and the inclusion criteria, individuals were included or excluded 
from the study and were notified of their participation status by telephone.  
 
Study Design 
This was pilot study with a convenience sample and a pre-test/post-test intervention with 
no specific control or placebo, all participants received the intervention. The intervention 
period consisted of daily supplementation of POMx™ capsules (2 capsules/day; 1 
capsule = 753 mg polyphenols) for a period of four weeks. The POMx™ capsules were 
purchased from Pom Wonderful LLC (Los Angeles, CA). Participants were asked to 
restrict intake of strawberries, or other berries, and green tea as intake of such foods 
could interfere with the effect of the pomegranate polyphenol supplement.  
Blood draws, blood pressure and anthropometrics (height, weight, and waist 
circumference) were obtained at the initial screening visit for both diabetic patients and 
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healthy controls. At the end of the four week intervention period subjects returned to 
Clinical Assessment Unit at NSCI for final anthropometric and blood pressure 
measurements and blood samples. A certified phlebotomist performed all blood draw 
samples from participants. Subjects were asked to maintain their typical diet, physical 
activity, and lifestyle during the study. For study participation subjects were compensated 
$30 at screen, week two and week four of the study or received $90 for the entire study.  
 
Subjects were instructed to complete detailed three day food records during the first and 
the final week of the supplementation period of the study. Participants were instructed on 
how to use the food records and also how accurately record food portions consumed. 
Participants recorded/described the type of food and amount of food consumed, as well as 
location (home, restaurant, with friends, or at work) and type of meal or snack during 
which the food was eaten (breakfast, morning snack, lunch, afternoon snack, dinner, or 
evening snack). Participants were also instructed to record the names of specific 
restaurants where food was consumed and names of menu items eaten. Submission of 
recipes and nutrition labels for foods prepared at participant’s home were requested in 
order to ensure accurate dietary analysis was performed. 
 
Measures: 
Blood Pressure: Systolic and diastolic blood pressure measurements were obtained using 
a portable blood pressure device with arm cuff, Spot Vital Signs Device (Welch Allyn, 
Skaneateles Falls, NY) 
 
37 
 
Anthropometrics: The Health-o-Meter weight tracking scale (2008 Sunbeam Products, 
Inc., Maitland, FL) were used to determine the participant’s body weight and the Gulick 
II tape measure (Vital Signs, Gay Mills, WI) was used to measure waist circumference at 
the super iliac crest in inches. Height was determined in centimeters with the 
standiometer in HES 307.  
 
Blood Draws: Serum separator tubes (SST) and tubes containing the anticoagulant 
EDTA were used in collecting 45-60 mL of blood from the participants after a period of 
fasting. Serum and plasma samples were stored at -80 ˚C until removed for analysis. In 
order to separate plasma and serum, centrifugation at 1464 g was performed for 10 
minutes at 4˚C using the Centrifuge 5810 R (Eppendorf, Hamburg, Germany) in Human 
Nutrition Laboratory at NSCI. Stillwater Medical Center (Stillwater, OK) performed 
analysis of each participant’s serum glucose, lipids, hemoglobin and hematocrit, platelets, 
and liver, renal, and thyroid function tests. Plasma not used for laboratory tests continued 
to be stored at -80˚C for later analysis of biomarkers of oxidative stress and 
inflammation.  
 
Polyphenol Content Analysis: Total phenolics and total ellagic acid content of 
individual capsules were determined by Brunswick Laboratories, Norton, MA.  
 
Macronutrient Content Analysis: Percent moisture, ash, protein, fat and carbohydrate 
was determined by the Robert M. Kerr Food and Agriculture Products Center, OSU, 
Stillwater, OK.  
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Analysis of Biomarkers of Oxidative Stress 
Blood samples from baseline and week four of the study were analyzed for biomarkers of 
oxidative stress. Biomarkers of oxidative stress present in the participant's blood samples 
that were measured for this study included oxidized LDL and malondialdehyde and 4-
hydroxynonenal (MDA and HNE). Serum oxidized LDL was measured in triplicate using 
an oxidized LDL competitive ELISA (Mercodia, Uppsala, Sweden) which is based on the 
monoclonal antibody 4E6 (mAb - 4E6). In this procedure, the oxidized LDL in the 
participant’s blood sample competes with a pre-determined amount of oxidized LDL in 
the microtiter well for binding with biotin-labeled specific antibodies. Following a 
washing to remove un-reactive sample components, the biotin-labeled antibody is 
identified with streptavidin. In the final steps, the bound conjugate is detected through its 
reaction with 3, 3!, 5, 5! - tetramethylbenzidine (TMB), stop solution is added, and the 
sample is read spectrophotometrically using the Synergy HT plate reader (BioTek 
Instruments, Inc., Winooski, VT) at 450 nm. The following flow diagram illustrates the 
principle of the procedure for oxidized LDL: 
 
25 µl of each sample diluted with 1,000 µl sample buffer 
 
50 µl of individually diluted samples placed in well plate in triplicate with calibrators 
 
50 µl antibody (mAb) added to all wells except the blank 
 
Samples incubated on shaker for 2 hours at room temperature  
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Samples washed 6 times manually with 350 µl wash buffer 
 
100 µl enzyme conjugate added to all wells 
 
Samples incubated on shaker for 1 hour at room temperature 
 
Samples washed 6 times manually with 350 µl wash buffer 
 
200 µl TMB added to all samples 
 
Samples incubated for 15 minutes, with no shaking 
 
50 µl stop solution added to samples 
 
Absorbance measured at 450 nm and results calculated 
 
Serum levels of MDA and HNE were determined with the Bioxytech® LPO – 586™ 
assay (OxisResearch™ Inc., Foster City, CA).  This assay for detecting lipid peroxidation 
is based on the reaction of MDA and 4-hydroxyalkenals with the chromogenic reagent, 
N-methyl-2-phenylindole at 45˚C. The acid solvent for this reaction is methanesulfonic 
acid. The sample is read spectrophotometrically using the Synergy HT plate reader 
(BioTek Instruments, Inc., Winooski, VT) at 586 nm. The following flow diagram 
illustrates the principle of the procedure for MDA and HNE: 
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200 µl of every sample placed in test tubes in triplicate 
 
650 µl R1 reagent added to samples 
 
Samples mixed by vortex 
 
150 µl R2 reagent added to samples 
 
Samples mixed and tube stopered 
 
Samples incubated for 60 minutes at 45˚C 
 
Samples centrifuged 
 
Absorbance measured at 586 nm and results calculated 
 
Analysis of Biomarkers of Inflammation 
Blood samples from baseline and week four of the study were analyzed for biomarkers of 
inflammation. Concentration of human C-reactive protein (CRP) present in the 
participant’s blood samples were measured for this study as a biomarker of inflammation.  
The procedure for determining serum levels of human CRP utilizes the quantitative 
sandwich enzyme immunoassay technique with a monoclonal antibody that is specific for 
CRP.  Standards and samples are added to the wells and CRP present in the plasma 
becomes bound by the immobilized antibody. Subsequent washing removes any unbound 
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substances and an enzyme-linked monoclonal antibody specific for CRP is then added to 
the wells. After a second wash, addition of a substrate solution causes color to develop in 
proportion to the amount of CRP that was bound in the first step of the procedure. A stop 
solution stops the color development and the intensity of the color will be measured 
spectrophotometrically with Synergy HT plate reader at 450 nm. The following flow 
diagram illustrates the principle of the procedure for CRP: 
 
10 µl of each sample diluted with 990 µl calibrator diluents RD5P (1X) 
 
100 µl of assay diluent RD 1F added to each well 
 
50 µl standard, control, and sample added to each well and incubated 2 hours 
 
Samples washed manually 4 times with 400 µl wash buffer 
 
200 µl CRP conjugate added to each well and incubated 2 hours. 
 
Samples washed manually 4 times with 400 µl wash buffer 
 
200 µl substrate solution added to each well, incubated 30 minutes, away from light 
 
50 µl stop solution added to each well 
 
Absorbance measured at 450 nm and results calculated 
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Dietary Analysis 
Participants’ detailed dietary food records were used to account for any dietary habits and 
dietary changes that could influence the results of the study. At completion of the study, 
three day food records from baseline and week four were entered and analyzed by ESHA 
Food Processor 9.1.0 (ESHA Research Inc., Salem, OR). The following dietary 
components were included in the analysis: energy (kcal), protein (g), fiber (g), total fat 
(g), vitamins A (mg), C (mg), and E (mg), copper (mg), iron (mg), & zinc (mg).  
 
Statistical Analysis 
Tests for biomarkers of oxidative stress and inflammation were performed in triplicate. 
Paired t-tests were performed to determine differences between pre- and post-intervention 
anthropometric and blood pressure measures as well as blood glucose, lipid profile, and 
liver, kidney, and thyroid function tests. Independent sample t-tests were used as 
appropriate to compare healthy controls to subjects with type 2 diabetes. Multiple 
regression was conducted for MDA and HNE. Changes in body weight, waist 
circumference, blood pressure, blood glucose, lipid profile, and liver, kidney, and thyroid 
function tests were analyzed as outcome measures of the study. Statistical significance 
was set at p < 0.05 (two-sided test) and all data analysis was performed with SPSS® 
version 16.0 (SPSS Inc., Chicago, IL).
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CHAPTER IV 
 
 
FINDINGS 
Nutrient Content of POMx Capsules 
Composition analysis was conducted to determine the macronutrient and polyphenol 
content of the POMx™ capsules (Table 3). Analysis revealed that two POMx™ capsules 
taken by participants each day added less than eight calories to the participants’ dietary 
intake. The two capsules are equivalent to 16 ounces of POM™ juice and provide the 
same polyphenol content without the additional calories (55; personal communications, 
POM™ Wonderful). Sixteen ounces of pomegranate juice or two POMx™ capsules are 
equivalent to approximately four to six whole fresh pomegranates. The two capsules 
provide 1801 mg carbohydrate (86.0 %), 6 mg fat (0.28 %), and 73 mg protein (3.5%) 
and have an ash content of 112.6 mg and a moisture content of 116 mg. The pomegranate 
supplements were also found to be high in phenolics as two POMx capsules provide 1506 
mg total phenolics and 372 mg total ellagic acid. Additionally POMx™ is comprised of a 
vegan capsule and vegetable stearate and silica as fillers.
44 
 
Baseline Characteristics 
Due to the fact that baseline characteristics between the healthy controls and the type 2 
diabetic subjects differed greatly in terms of pathophysiological characteristics, the 
primary objective of our study was not to compare between group differences before and 
after POMx™ supplementation. Rather, the primary objective was to compare 
differences from baseline to week four of the study within each individual group. 
However, an independent sample t-test and multiple regression was conducted as a 
secondary analysis between groups for MDA and HNE. 
 
The baseline characteristics for the subjects are outlined in Table 4. A total of 17 
subjects, 9 healthy controls and 8 subjects with type 2 diabetes completed the study. The 
subjects were predominantly female with only two male subjects in the diabetic study 
group and no male subjects in the healthy control group. The duration of diabetes among 
the eight diabetic subjects ranged from four months to three years. Six of the diabetic 
subjects were on daily prescription medications for diabetes management. Medications 
included Metformin, Byetta, Actos, and Avandia. None of the subjects discontinued the 
study due to any adverse events. Only minor adverse events were reported and such 
events included one report of increased appetite after taking the capsules and one report 
of dizziness and nausea on two occasions. However, these effects subsided early in the 
study. One healthy control was excluded due to having high triglyceride levels (420 
mg/dL) at the end of the fourth week of the study. These changes were most likely due to 
dietary changes that had taken place between week one and week four of the study.  
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Daily aspirin use, commonly recommended to lower risk of heart attack, was reported by 
only one subject in the diabetic group. Seven healthy controls and four subjects with type 
2 diabetes reported using supplements, mainly a multivitamin or mineral, at the screening 
visit and continued throughout the duration of the study. Three total subjects reported 
antioxidant supplement intake in the past. However, none of the subjects took such 
supplements during the course of the study. One healthy control and one diabetic subject 
reported taking a fish oil supplement at the screening visit and continued throughout the 
duration of the study. Blood pressure medication use was reported by two diabetic 
subjects during the study.  
 
All diabetic subjects were obese as determined by their body mass index (BMI) at the 
initial screen. The mean BMI for the diabetic group was 35.3 kg/m2. Diabetic males had 
waist circumferences > 40 inches and diabetic females had waist circumferences > 35 
inches. The mean waist circumference of the diabetic group was 42.4 inches. The healthy 
controls were required to have a normal BMI and waist circumference < 40 inches for 
males and < 35 inches for females at the screening visit to qualify for the study. The 
mean BMI for the control group was 23.3 kg/m2 and the mean waist circumference was 
31.06 inches. 
 
A significant decrease (p < 0.05) in BMI (35.26 ± 10.28 kg/m2 to 34.81 ± 9.98 kg/m2) 
and bodyweight (99.32 ± 10.28 kg to 98.05 ± 9.98 kg) was observed at week four in the 
diabetic group. Such decreases were not supported by corresponding differences in 
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dietary data for macronutrients. Significant weight and BMI changes were not observed 
in the healthy controls from baseline to week four.  
 
Blood Glucose, Blood Pressure, and Lipid Profile 
Supplementation with POMx™ capsules did not worsen diabetic parameters such as 
glucose, mean blood glucose, hemoglobin A1c, or glycosylated hemoglobin in the 
diabetic subjects or healthy controls (Table 5). Significant differences were not observed 
in the mean blood glucose values of the healthy controls (85.11 ± 4.48 mg/dL to 85.67 ± 
8.03 mg/dL; p > 0.05) after POMx™ supplementation. Normal fasting blood glucose 
level is less than 100 mg/dL (56). Likewise, the mean blood glucose for the diabetic 
group (105.88 ± 29.57 mg/dL to 114.25 ± 33.36 mg/dL; p > 0.05) did not significantly 
differ after the supplementation period. Blood glucose levels greater than 126 mg/dL are 
used to diagnose diabetes (56). 
 
The LDL-cholesterol levels of the healthy controls increased significantly by 7% from 
baseline to week four of the study (109.22 ± 27.87 mg/dL to 117.22 ± 30.05 mg/dL; p < 
0.05). The reference value for LDL-cholesterol is less than 100 mg/dL (57). The mean 
LDL-cholesterol level of the diabetic group did not significantly increase during the 
study. At baseline the mean LDL-cholesterol level of the diabetic subjects was 87.50 
mg/dL ± 43.09, which met reference value and at week four the mean LDL-cholesterol 
level was 103.75 ± 27.42 mg/dL. Supplementation with POMx™ did not significantly 
affect blood pressure or other parameters of the lipid profile such as total cholesterol, 
triglycerides, HDL-cholesterol, VLDL-cholesterol, LDL/HDL ratio, or chol/HDL ratio 
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(Table 5). Also, the mean values for these parameters in both the diabetic group and the 
healthy controls remained within what was considered the normal range at both baseline 
and week four (total cholesterol: < 200 mg/dL, triglycerides: < 150 mg/dL, HDL-
cholesterol: 40-60 mg/dL) (57). 
 
Safety Parameters 
Aspartate aminotransferase (AST) levels were significantly increased (21.78 ± 4.29 U/L 
to 25.33 ± 6.82 U/L; p < 0.05) by 16% in healthy controls from screen to week four and 
there was a significant decrease of 10% (36.88 ± 13.47 U/L to 33.13 ± 10.05 U/L; p < 
0.05) in alanine aminotransferase (ALT) levels from screen to week four in the diabetic 
group (Table 6). All liver parameters were within what is considered the normal range, 
including the significant differences in AST in healthy controls and ALT in diabetic 
subjects (AST: 14-36 U/L; ALT: 7-56 U/L). Electrolyte levels, renal function, and 
hematology were unaffected by POMx™ supplementation as all laboratory values were 
within normal limits and no significant differences were detected.  
 
Biomarkers of Oxidative Stress 
Two measures of oxidative stress were analyzed to determine the effectiveness of 
POMx™ as an antioxidant in both diabetic subjects and healthy controls. Oxidized LDL 
levels did not significantly change in the diabetic subjects after supplementation with 
POMx™ (201.22 ± 34.87 U/L to 183 ± 49.02 U/L). Likewise, ox-LDL levels of the 
healthy controls did not differ significantly (182.91 ± 32.34 U/L to 173.59 ± 21.83 U/L). 
Baseline levels of the lipid peroxidation by-products malondialdehyde (MDA) and 4-
hydroxynonenal (HNE) were significantly (p < 0.05) higher, by 45.5%, than that of the 
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healthy controls (Figure 1). Mean values of MDA and HNE were not significantly 
reduced in the healthy controls after supplementation with POMx™ (0.96 ± 1.02 µM to 
1.02 ± 0.15 µM; p > 0.05). However mean levels were significantly reduced by as much 
as 40% in the diabetic group (1.76 ± 0.02 µM to 1.06 ± 0.26 µM; p < 0.05) after 
supplementation. The mean difference from baseline to week four in the diabetic group 
was significantly (p < 0.05) different from the mean difference observed in the healthy 
controls. At week four a significant difference was no longer observed between the raw 
mean scores of the diabetic group and the healthy controls.  
 
Biomarkers of Inflammation 
C-reactive protein (CRP) was used to determine the effect of POMx™ supplementation 
on inflammation. Results indicated that CRP levels were unaffected by POMx™ 
supplementation in both the healthy control and the diabetic group. 
 
Dietary Analysis 
The average caloric intake of both the healthy controls and diabetic participants did not 
change significantly from baseline to week four of the study (Table 7). Dietary data was 
not collected for week two and week three of the study. The POMx™ capsule was not 
included in the dietary analysis, as the supplement was not considered part of the 
participants’ normal dietary pattern. Also, contribution of multivitamins and mineral 
supplements to the participant’s dietary intake was not included in the dietary analysis. At 
baseline, the macronutrient composition for healthy controls was 50.7% carbohydrate, 
16.8% protein, and 35.3% fat of total calories on average. The macronutrient composition 
for diabetic subjects was 44.4% carbohydrate, 19.2% protein, and 38.1% fat of total 
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calories on average. Macronutrient intake was not significantly different at baseline and 
week four among healthy controls or diabetic subjects. The mean cholesterol intake of the 
healthy controls was 180.57 ± 69.85 mg/day at baseline and 144.51 ± 65.79 mg/day at 
week four. The mean cholesterol intake of the diabetic participants was 256.11 ± 179.52 
mg/day at baseline and 236.83 ± 164.64 mg/day at week four of the intervention. The 
diabetic group had a lower mean intake of fiber than the healthy controls at both baseline 
and week four (healthy control: 22.53 ± 5.33 g/day to 19.75 ± 7.11 g/day; diabetic: 13.46 
± 4.83 g/day to 12.11 ± 3.64 g/day).  
Intake of micronutrients also did not significantly differ from baseline to week four. The 
healthy controls appear to have higher mean intakes of vitamin C than the diabetic 
subjects (healthy control: 123.30 ± 55.90 mg to 278.77 ± 453.17 mg; diabetic subjects: 
69.25 ± 44.85 mg to 51.56 ± 36.33 mg; p > 0.05). However, between group comparisons 
for significance were not conducted for the purpose of this study. The mean vitamin E 
intake for the healthy controls was 6.66 ± 4.97 mg at baseline and 3.63 ± 2.36 mg at week 
four. The mean vitamin E intake in the diabetic group was 5.05 ± 4.60 mg at baseline and 
4.21 ± 5.46 mg at week four.  
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Table 3: Composition of POMx™ capsules1 
Component  (weight) Weight (mg)   
Carbohydrates (mg)                                       1801 
Hexane Extract (mg) 5.86 
Protein (mg) 72.5 
Ash (mg) 112.6 
Moisture (mg) 116.08 
Total Ellagic Acid (mg) 372 
Total Phenolics (mg)* 1505.28   
1 Data presented per 2101 mg (2 capsules). Source: Pom Wonderful 
(LA,CA,USA) 
* Expressed as mg gallic acid equivalents 
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Table 4. Baseline characteristics of healthy controls and diabetic subjects 
  
Characteristics  Healthy Controls   Diabetic Subjects 
Gender 
          Male/Female (n/n)  
 
0 / 9 2 / 6 
Age (mean, SD) 
 
47.1, 6.3 52.4, 13.3 
Weight kg (mean, SD) 
 
62.6, 10.3 99.3, 29.1 
Height cm (mean, SD) 
 
163.7, 6.0 167.6, 7.2 
BMI kg/m2 
 
23.3, 3.0 35.3, 10.3 
Waist Circumference in (mean, SD) 31.06, 2.3 42.4, 7.9 
Supplement Use (%) 
 
7 (78%) 4 (50%) 
          Vitamin/Mineral (%) 7 (78%) 4 (50%) 
          Herb or Botanical (%) 0 (0%) 0 (0%) 
          Antioxidant in the past(%) 2(22%) 1 (13%) 
          Fish Oil  (%) 
 
1 (11%) 
   
1 (13%) 
 
Blood Pressure Medication (%) 0 (0%) 2(25%) 
 
Diabetic Medication (%) 
 
0 (0%) 
   
6 (75%) 
Aspirin Use (%) 
 
0 (0%) 1 (13%) 
Other Medications (%)   1 (11%)       6 (75%)   
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Table 5. Effects of POMx™ supplementation on blood glucose, blood pressure, and lipid levels1 
  Healthy Controls (n=9) Diabetic Subjects (n=8) 
Variables Screen Week 4 Screen  Week 4 
Glucose (mg/dL) 85.11 ± 4.48  85.67 ± 8.03 105.88 ± 29.57 114.25 ± 33.36 
Mean blood glucose (mg/dL) 97.33 ± 16.93 97.33 ± 19.01 121.25 ± 16.73 116.38 ± 11.56 
Hemoglobin A1C (%) 5.51 ± 0.51 5.51 ± 0.57 6.22 ± 0.50 6.08 ± 0.35 
Glycosylated hemoglobin (%) 6.45 ± 0.76 6.45 ± 0.85 7.51 ± 0.75 7.31 ± 0.53 
Insulin (U/L) 7.77 ± 2.44 10.52 ± 12.06 18.61 ± 7.30 19.06 ± 6.03 
Systolic blood pressure (mmHg) 114.67 ± 6.18 115.33 ± 5.81 129.00 ± 18.19 134.25 ± 23.81  
Diastolic blood pressure (mmHg) 71.33 ± 7.37 72.67 ± 9.25 81.63 ± 8.25 79.88 ± 5.17 
Cholesterol (mg/dL) 187.89 ± 30.16 195.56 ± 30.53 182.13 ± 40.47 181.50 ± 36.73 
Triglycerides (mg/dL) 77.11 ± 18.43 77.56 ± 26.88  149.75 ± 94.73 135.63 ± 66.06 
LDL-cholesterol (mg/dL) 109.22 ± 27.87 117.22 ± 30.05* 87.50 ± 43.09 103.75 ± 27.42 
HDL-cholesterol (mg/dL) 63.11 ± 7.56 62.89 ± 9.35 51.75 ± 11.45 50.38 ± 11.03 
VLDL-cholesterol (mg/dL) 15.33 ± 3.67 15.44 ± 5.29 30.00 ± 19.04 27.25 ± 13.32 
LDL/HDL ratio 1.76 ± 0.52 1.93 ± 0.66 1.98 ± 0.68 2.15 ± 0.75 
Chol/HDL ratio 2.89 ± 0.78 3.05 ± 0.88 3.63 ± 0.92 3.58 ± 0.96 
1 Data are mean ± SD 
    *significantly different from baseline (p < 0.05) 
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Table 6. Effects of POMx™ supplementation on safety parameters1 
    
Healthy Controls (n=9) Diabetic Subjects (n=8) 
Variables Screen Week 4 Screen Week 4 
Aspartate aminotransferase (U/L) 21.78 ± 4.29 25.33 ± 6.82* 30.00 ± 9.71 30.75 ± 9.42 
Alanine aminotransferase (U/L) 25.33 ± 8.23 27.22 ± 11.94 36.88 ± 13.47 33.13 ± 10.05* 
Alkaline Phosphatase (U/L) 72.89 ± 8.23 74.22 ± 24.79 91.50 ± 17.96  87.50 ± 11.07 
Bilirubin, Total (mg/dL) 0.43 ± 0.26 0.39 ± 0.24 0.33 ± 0.10 0.43 ± 0.18 
Total Protein (g/dL) 6.94 ± 0.32 6.96 ± 0.38 7.15 ± 0.33 7.23 ± 0.44 
Albumin (g/dL) 4.18 ± 0.31 4.20 ± 0.25 4.14 ± 0.32 4.19 ± 0.32 
Globulin (g/dL) 2.78 ± 0.29 2.76 ± 0.22 3.00 ± 0.21 3.05 ± 0.21 
Albumin/Globulin ratio 1.51 ± 0.20 1.53 ± 0.14 1.40 ± 0.17 1.38 ± 0.12 
Sodium (mEq/L) 139.78 ± 1.79 139.89 ± 2.67 140.38 ± 3.02 140.50 ± 2.73  
Potassium (mEq/L) 4.28 ± 0.42 4.21 ± 0.31 4.25 ± 0.18 4.25 ± 0.37 
Chloride (mEq/L) 106.56 ± 2.60 107.56 ± 1.67 105.00 ± 1.20 105.50 ± 1.31 
Calcium (mg/dL) 9.60 ± 0.46 9.40 ± 0.44 9.51 ± 0.52 9.49 ± 0.39 
Thyroxine (T4) (ug/dL) 6.91 ± 1.55 6.42 ± 1.47 8.14 ± 2.20 7.70 ± 1.55 
T3 Uptake (%) 31.22 ± 3.31 31.56 ± 3.48 29.10 ± 1.70 30.79 ± 2.75 
Blood urea nitrogen (mg/dL) 12.11 ± 2.67 13.00 4.12 15.25 ± 3.92 15.50 ± 2.93 
Creatinine (mg/dL) 0.82 ± 0.20  0.80 ± 0.15 0.83 ± 0.18 0.86 ± 0.18 
Blood urea nitrogen/Creatinine ratio 14.93 ± 2.72 16.28 ± 5.01 18.39 ± 2.71 18.64 ± 5.40 
White blood cell (K/mm3) 5.17 ± 0.77 5.09 ± 1.18 7.89 ± 2.01 7.40 ± 1.80 
Red blood cell (M/mm3) 4.45 ± 0.32 4.49 ± 0.33 4.78 ± 0.25 4.74 ± 0.28 
Hemoglobin (gm/dL) 13.74 ± 0.90 13.86 ± 0.91 13.69 ± 0.69 13.58 ± 0.71 
Hematocrit (%) 40.87 ± 2.82 40.92 ± 2.51 41.23 ± 2.30 40.84 ± 2.28 
Platelet Count 271.22 ± 59.16 269.78 ± 63.44 259.00 ± 70.07 276.13 ± 55.24 
1 Data are mean ± SD 
    * significantly different from baseline (p < 0.05) 
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Table 7. Dietary analysis of participant's intake from week 1 and week 4 of intervention1,2 
  Healthy Controls (n=9) Diabetic Subjects (n=8) 
Nutrient Screen Week 4 Screen  Week 4 
Energy (kcal) 1679.42 ± 285.13 1739.05 ± 462.52 1266.32 ± 413.65 1273.38 ± 412.62 
Protein (g) 70.71 ± 10.48 62.14 ± 15.29 60.74 ± 11.70 70.95 ± 23.45 
Carbohydrate (g) 213.00 ± 45.42 254.90 ± 113.23 140.59 ± 50.55 129.42 ± 51.92 
Fiber (g) 22.53 ± 5.33 19.75 ± 7.11 13.46 ± 4.83 12.11 ± 3.64 
Total fat (g) 65.94 ± 16.21 55.62 ± 21.71 53.64 ± 22.81 54.98 ± 20.18 
Saturated fat (g) 19.07 ± 6.40 15.74 ± 8.85 15.09 ±7.05 18.91 ± 6.53 
Monounsaturated fat (g) 17.18 ± 6.37 14.90 ± 7.80 13.71 ± 8.25 14.54 ± 7.11 
Polyunsaturated fat (g) 12.36 ± 5.32 9.00 ± 5.03 9.91 ± 6.68 6.90 ± 5.07 
Cholesterol (mg) 180.57 ± 69.85 144.51 ± 65.79 256.11 ± 179.52 236.83 ± 164.64 
Carotenoids (RE) 773.01 ± 443.40 434.37 ± 240.67 486.79 ± 294.38 428.45 ± 207.05 
Vitamin C (mg) 123.30 ± 55.90 278.77 ± 453.17 69.25 ± 44.85 51.61 ± 36.33 
Vitamin E (mg) 6.66 ± 4.97 3.63 ± 2.36 5.05 ± 4.60 4.21 ± 5.46 
Copper (mg) 0.99 ± 0.32 0.78 ± 0.40 0.60 ± 0.23 0.59 ± 0.23 
Iron (mg) 13.82 ± 3.87 12.95 ± 3.06 9.85 ± 4.24 12.11 ± 6.02 
Zinc (mg) 8.39 ± 2.24 7.30 ± 2.43 4.93 ± 1.85 7.43 ± 2.99 
1 Data are mean ± SD 
2 Data was collected from 3 day food records 
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Figure 1. Effects of POMx™ supplementation on biomarkers of oxidative stress1 
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Figure 2. Effects of POMx™ supplementation on biomarkers of inflammation1 
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CHAPTER V 
 
 
CONCLUSION 
In the present study, we have shown the effects of pomegranate polyphenol 
supplementation on biomarkers of oxidative stress and inflammation in subjects with 
abdominal adiposity and type 2 diabetes versus healthy controls. To our knowledge this is 
the first study with both type 2 diabetic subjects and healthy controls reporting the impact 
of POMx™ capsules on safety parameters as well as biomarkers of oxidative stress and 
inflammation. Based on our findings, it appears that the POMx™ capsules are safe and 
well tolerated in subjects with type 2 diabetes and healthy controls. Though the capsules 
did not contribute to significant changes in ox-LDL or CRP, they did demonstrate the 
potential to improve lipid peroxidation in the diabetic subjects as determined by the 
significant decrease in mean MDA and HNE levels. Confirmation of our findings 
regarding the beneficial effects of the POMx™ capsules on lipid peroxidation could be 
important in reducing diabetic complications associated with cardiovascular disease.  
 
Diabetes has been reported to be a powerful independent risk factor for the development 
of coronary artery disease, stroke and peripheral arterial disease, as well as 
atherosclerosis, which is responsible for eighty percent of all deaths among patients with 
diabetes (53). Three major mechanisms exist to explain the pathological alterations 
observed in diabetic vasculature as determined by human and animal studies (53). 
58 
 
These mechanisms include non-enzymatic glycosylation of proteins and lipids, cellular 
protein kinase C (PKC) activation of oxidative stress pathways, and depletion of natural 
antioxidants and production of free radicals as a result of prolonged exposure to 
hyperglycemia. The inflammatory-immune response as well as oxidative stress reactions 
and generation of free radicals induced by hyperglycemia underlie the etiology for the 
cardiovascular complications and mortality associated with type 2 diabetes (16).  
 
Diabetic patients are at an increased risk of developing heart disease. The hyperglycemia 
in type 2 diabetes stimulates oxidative stress reactions and inflammatory-immune 
responses that play a key role in the development of diabetes related cardiovascular 
complications, such as atherosclerosis (16). As a result of the increased oxidative stress, 
diabetic patients have been found to have increased levels of lipid peroxidation, an 
indicator of oxidative stress, and high concentrations of the lipid peroxidation by-product 
malondialdehyde (MDA) (53,58). In a previous study, Aviram et al. (2000) showed that 
under conditions of oxidative stress macrophages can undergo lipid peroxidation and 
subsequently oxidize LDL (6). The oxidation of LDL by macrophages is considered to be 
a key event in the early stages of atherogenesis and is also associated with the further 
uptake of oxidized LDL which leads to cholesterol accumulation in the macrophage and 
thus formation of a foam cells.  
 
In our study, ox-LDL levels did not significantly differ in either the healthy controls or 
the diabetic subjects after four weeks of supplementation with POMx™. Likewise 
significant changes were not observed in levels of CRP. These null results could be due 
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to the fact that the study duration of four weeks was not long enough to detect significant 
changes in ox-LDL or CRP.  
 
However, supplementation with POMx did significantly impact lipid peroxidation in the 
diabetic group as determined by analysis of MDA and HNE. The diabetic subjects 
presented significantly higher mean levels of the lipid peroxidation by-products MDA 
and HNE at baseline. Higher levels at baseline can best be explained by the fact that 
diabetic patients experience increased levels of oxidative stress as a result of 
hyperglycemia, which contributes to lipid peroxidation (53,58). The decrease in MDA 
and HNE from baseline to week four in the diabetic group was found to be statistically 
significant and the mean difference in MDA and HNE was also significantly greater in 
the diabetic subjects than in the healthy controls. Interestingly, at week four a significant 
difference was not detected between the healthy controls and the diabetic subjects, 
indicating that the MDA and HNE levels of the diabetic subjects had been lowered to a 
level comparable to that of the healthy controls. Thus POMx™ did exert potential 
beneficial cardiovascular health effects by reducing lipid peroxidation in our study.  
 
The cardiovascular health effects of pomegranates related to impact on oxidative stress 
and lipid peroxidation have been well investigated in animal models of atherosclerosis. In 
atherosclerotic apolipoprotein E-deficient (E0) mice PJ (6.25 or 12.5 µL/d [equivalent to 
0.175 and 0.350 µmol total polyphenols]) reduced plasma lipid peroxidation and 
increased total antioxidant status in comparison to control E0 mice supplemented with 
water (6). Pomegranate juice also reduced susceptibility of LDL from E0 mice to copper 
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ion-induced oxidation and attenuated susceptibility of LDL to the oxidation associated 
with the progressive increase in age. Supplementation with PJ reduced lipid peroxidation 
of mouse peritoneal macrophages (MPMs) by as much as 53% in comparison to MPMs 
isolated from control mice. Additionally, PJ reduced atherosclerotic lesions and 
decreased the number of lipid-laden foam cells in E0 mice.  
 
The beneficial health effects of pomegranates on biomarkers of oxidative stress were also 
demonstrated in humans (6). Supplementation with 50 ml PJ/d (1.5 mmol total 
polyphenols) significantly reduced susceptibility to lipid peroxidation by 6% in healthy 
male subjects (6). The inhibitory effect of PJ on lipid peroxidation was maintained for an 
additional two weeks after the PJ supplementation ended. A significant increase was also 
observed in plasma total antioxidant status after two weeks of PJ consumption. 
Pomegranate juice was found to reduce LDL aggregation in seven of the thirteen 
subjects, although the mean value was not statistically significant. Decreases in platelet 
aggregation are important because the atherogenecity of LDL is also attributed to 
aggregation in addition to oxidative modification. Once LDL becomes oxidized it is more 
prone to aggregation. 
 
The results from both human and animal studies suggest antiatherogenic properties of PJ 
as related to its inhibitory effect on lipid peroxidation in plasma, in lipoproteins, and in 
macrophages (6). PJ supplementation significantly inhibited the progression of 
atherosclerotic lesions and inhibited atherogenic modifications to LDL. The strong 
antioxidant capacity of PJ to protect against lipid peroxidation is believed to be the 
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central link for the antiatherogenic actions of PJ on lipoproteins, macrophages, and 
platelets. It seems that similar results may be obtained with POMx™ supplementation. 
However, our results must be confirmed in future clinical trials.  
 
Our study was the first human study reporting the effects of POMx™ supplementation on 
biomarkers of oxidative stress and inflammation in subjects with type 2 diabetes as well 
as healthy controls. Thus it was important for us to assess a variety of safety parameters 
including liver and kidney function tests in order to identify any possible negative health 
outcomes. Overall our results indicate that kidney and liver function as well as 
hematology parameters were unaffected by supplementation with POMx™. Although, 
AST levels in the healthy controls significantly (p < 0.05) increased and ALT levels 
significantly (p < 0.05) decreased, neither result was clinically abnormal. Even though 
these values were found to be statistically significant, they still fall within what is 
considered the normal healthy range for adults. Thus, these significant differences are not 
a cause for safety concerns. However our findings need to be confirmed in further 
studies. 
 
In a similar four week study, Heber et al. (2007) assessed the safety and antioxidant 
activity of pomegranate polyphenol extracts (POMx™ capsules) in non-diabetic 
overweight (BMI of 25 – 32 kg/m2) individuals with increased waist size ( > 40 inches in 
males and > 35 inches in females) (54). A formal assessment of adverse reactions and a 
comprehensive series of blood tests for toxicity were conducted for comparison between 
supplement and placebo groups. None of the subjects discontinued the study due to 
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adverse events and there were no apparent treatment-related changes of clinical 
significance. None of the laboratory results were outside of the normal range in any of the 
chemistry, hematology, or urinalysis tests. Their results were similar to the ones obtained 
in our study in that all of the safety parameters were within the normal range. Although 
AST levels in healthy controls and ALT levels in diabetic subjects in our study were 
significantly different (p < 0.05) from screen to week four these values were still within 
the normal safe range. Interfering factors such as change in medications, exercise, or 
intramuscular injections could contribute to increases in AST levels (59).  
 
Clearly, hyperglycemia is an established risk factor for cardiovascular disease (CVD) and 
increased oxidative stress and inflammation. In our clinical investigation, four week 
supplementation with two POMx™ capsules daily did not significantly affect diabetic 
parameters. Although we detected a decrease of 4% in mean blood glucose and decrease 
of 2% in hemoglobin A1c these results were not statistically significant. Rosenblat et al. 
(2006) examined the effects of three month consumption of PJ (50 mL/day; 1.5 mmol 
total polyphenols) by diabetic subjects and healthy controls and found that PJ 
consumption resulted in a non-significant reduction of 8% in serum glucose levels with 
no significant effects on blood hemoglobin A1c (53). Likewise, a non-significant 
decrease in serum insulin levels was also reported. Thus despite the presence of sugars in 
PJ, serum diabetic parameters were not worsened.  
 
These results were similar to the results in our present study as both the POMx™ 
capsules and PJ resulted non-significant decreases in glucose levels and hemoglobin A1c 
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in diabetic subjects and diabetic parameters were not worsened. It is possible that the 
percent decrease was larger for the subjects in Rosenblat’s study because our subjects had 
mean blood glucose levels of 105.88 ± 29.57 mg/dL at the screening visit, whereas the 
subjects in Roseblat’s study had blood glucose levels of 160 mg%. Additionally, 
differences between their study and ours could result from differences in type of 
supplementation given, as they used a specially formulated pomegranate juice developed 
in their laboratory and we used commercially formulated capsules by PomWonderful 
LLC.  
 
In addition to hyperglycemia being a risk factor for CVD, elevated blood pressure levels 
also increase the risk of developing CVD, especially in subjects with a history of diabetes 
(60). The increased oxidative stress from hyperglycemia may play a role in elevating 
blood pressure by a direct vasoconstrictor effect or by indirectly reducing the activity of 
vasodilators such as nitric oxide. Hypertension is of critical concern in patients with 
diabetes because it can accelerate both macrovascular and microvascular complications. 
Although between group analysis was not performed for significance in our current study 
for blood pressure measures, it is interesting to note that the diabetic subjects began the 
study with blood pressure values that were 12% higher than the healthy controls. The 
blood pressure values of the diabetic subjects were within what is considered the pre-
hypertensive range. 
 
The results of our study indicate that systolic blood pressure was unaffected by POMx™ 
supplementation in both the control and the diabetic subject groups. However, in a 
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mechanistic study with diabetic hypertensive rats, administration of PJ (100 mg/kg/day or 
300 mg/kg/day) resulted in a significant reduction in mean arterial blood pressure (60). 
However, the mean arterial blood pressure of rats with diabetes only, remained 
unchanged after supplementation with PJ.  
 
Although it is difficult to make adequate comparisons between the results of our human 
study and this mechanistic study in animals, a two week clinical trial with ten 
hypertensive patients, two of which were also diabetic (serum glucose >126 mg/dL), 
found PJ (50 ml, 1.5 mmol total polyphenols per day) to have an effect on blood pressure, 
as there was a significant reduction in systolic blood pressure (5). The difference in 
findings between our study and their study may be related to the fact that the subjects in 
our study did not have a clinical diagnosis of hypertension. The hypertensive patients in 
the aforementioned study presented mean blood pressure levels of 155 ± 7/ 83 ± 7 
mmHg, whereas the subjects in our study had a lower mean blood pressure levels at 
baseline (controls: 114.67 ± 6.18/ 71.33 ± 7.37 mmHg; diabetic: 129.00 ± 18.19/ 81.63 ± 
8.25 mmHg). Based on the results of both the clinical study and the mechanistic study, it 
appears that PJ has a greater impact on blood pressure in the presence of more highly 
elevated blood pressure values and also in the presence of a combination of diabetes and 
hypertension. It is important to mention that in both of the comparison studies PJ, 
specially formulated in the researcher’s laboratory, was used versus our commercially 
produced POMx™ capsules, which could account for some of the variation in outcomes.  
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Elevated lipid levels, often present in patients with diabetes, can lead to subsequent 
cardiovascular complications. In fact, high circulating levels of cholesterol, specifically 
LDL, has been implicated as a major contributor in the atherosclerotic process. In our 
study, supplementation with POMx™ capsules for four weeks did not result in a 
significant decrease in lipid levels in any of the subjects. The only statistically significant 
result was the increase in mean LDL-cholesterol from screen to week four in the healthy 
subjects. The mean LDL-cholesterol levels of the healthy controls exceeded the reference 
value (LDL-cholesterol: < 100 mg/dL) at baseline and increased significantly at week 
four. Such an increase may be the result of dietary changes among the healthy controls or 
from interfering factors such as drug or supplement intake, stress, or unknown 
atherosclerosis (59). However, it is important to note that our dietary analysis did not 
reveal any significant differences in intake of total fat or saturated fat from baseline to 
week four.  
 
Aviram et al. (2000) also found administration of 50 ml PJ/d (1.5 mmol total 
polyphenols) to have no significant effects on plasma lipid levels, including total 
cholesterol, LDL-cholesterol, VLDL-cholesterol, HDL-cholesterol and triglyceride 
concentrations in healthy male subjects (6). Although similar results were obtained it 
should be noted that pomegranates (‘Wonderful’ cultivar) were handpicked and used to 
make specially formulated PJ in their laboratory for their study. 
 
Despite the fact that lipid profile was not improved in our study, PJ has demonstrated the 
potential to improve aspects of the lipid profile of diabetic hyperlipidemic subjects. 
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Esmaillzadeh et al. (2006) assessed the effects of 40 g/day concentrated pomegranate 
juice (CPJ) (875 mg/ 100g total polyphenols) consumption for eight weeks on lipid 
profiles in type 2 diabetic patients (fasting blood sugar ≥ 126 mg/dL) with hyperlipidemia 
(total cholesterol or triglycerides of ≥ 200 mg/dL) and significant reductions in total 
cholesterol (p < 0.006), LDL-cholesterol (p < 0.006), LDL/HDL-cholesterol (p < 0.001), 
and total cholesterol/HDL-cholesterol were observed (61). Differences between their 
findings and findings of our study may be related to differential effects of the 
intervention, CPJ used in their study for eight weeks versus POMx™ supplement used in 
our study for four weeks. Furthermore, we did not include subjects with hyperlipidemia 
and thus the normal triglycerides and lower glucose levels in our subjects may have 
contributed to the null effects of POMx™ on lipids profiles in our study.  
 
The POMx™ supplements (POM Wonderful LLC, LA, CA) used in are study were 
prepared from partially juice-pressed whole fruit, arils, and seeds (54). The capsules 
contain the same monomeric and oligomeric ellagitannins as the POM Wonderful™ PJ, 
but lack the sugars and calories that are naturally present in the juice form. POM 
Wonderful LLC claims that one POMx™ capsule contains 1,000 mg total natural 
polyphenol extract on their website http://www.pompills.com/pills/product_pills.aspx. 
Yet, the composition analysis conducted by Brunswick Laboratories, Norton, MA in our 
study revealed that one POMx™ capsule provides 753 mg total pomegranate polyphenols 
or 1506 mg total phenolics per two capsules.  
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Differences in polyphenol content could be related to temperature, humidity, soil 
conditions or some step of the collection and manufacturing process (62). Additionally 
labeling claims may not accurately reflect the true polyphenol content of the capsule (63). 
For example, in a previous study by Seeram et al. (2006), labeling information for total 
tea polyphenols in green tea dietary supplements failed to contain the claimed amount 
(63). Reliable labeling information as well as standardized manufacturing practices are 
needed to ensure quality control of dietary supplements. However, despite the 
discrepancies between the labeling claims made by POM Wonderful™ and our analysis 
as determined by Brunswick laboratories, 1506 mg total phenolics per day is a substantial 
amount for supplementation. 
 
The POMx™ capsules used by Heber et al. (2007) were also obtained from 
PomWonderful LLC (54). However analysis of their POMx™ capsules indicated that 
each capsule containing 1,000 mg extract provided 610 mg gallic acid equivalents 
(GAEs) while our analysis, conducted by Brunswick Laboratories, found each capsule to 
contain 753 mg GAEs. Although in both studies capsules were purchased from the same 
distributor, it is possible that cultivar differences could have influenced the total phenol 
content of the capsules as well as differences in storage conditions and analytical 
techniques. Cultivation changes such as variations in plantation season have been found 
to influence total phenolic content in strawberries according to light and temperature 
(64). Also, harvest time affects the content of ellagic acid in strawberries, presumably as 
a result of difference in temperature and rainfall (65). Phenolic content may change from 
year to year and it is quite possible that the pomegranates used for our capsules were 
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from a different batch than those used in the study conducted by Heber et al. (2007). 
Despite the variation in GAEs, results from their study and ours are comparable in terms 
of pomegranate polyphenol supplement used and composition. The subject population 
studied was also similar in that both studies included subjects with increased waist size 
and BMI.  
 
Overall, mean caloric intake did not significantly differ from baseline to week four in 
either the diabetic group or the healthy controls. It is possible that underreporting of 
dietary intake occurred in our study as the mean caloric intake of the diabetic subjects 
seemed exceptionally low (1266.32 ± 413.65 kcal to 1273 ± 412.62 kcal). Previous 
studies investigating the accuracy of self-reported dietary intake have found that 
underreporting of total caloric intake and high fat foods occurs frequently, especially 
among obese participants (66,67). The macronutrient composition of both groups was 
similar to the recommended range outlined in Dietary Guidelines for Americans (DGA) 
2005, which states that 45-65% of total calories should come from carbohydrate sources, 
10-35% from protein, and 20-35% from fat (68). It appeared that the diabetic group had a 
lower mean intake of carbohydrate, a higher mean intake of protein, and a higher intake 
of fat as compared to the healthy controls. However, this data may have been skewed due 
to the fact that the mean reported caloric intake was low among the diabetic subjects.  
 
All of the participants had mean LDL-cholesterol levels below 130 mg/dL, thus the mean 
dietary cholesterol intake in both groups should be less than 300 mg/dL (68). Both groups 
met this recommendation. However, the diabetic subjects did report a higher mean 
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dietary cholesterol intake than the healthy controls. The mean intake of dietary fiber was 
higher among healthy controls and more closely met the recommendations of the DGA 
2005, which is 14 grams of fiber per every 1,000 calories (68).The healthy controls also 
had a higher mean intake of vitamin C than the diabetic subjects and intake exceeded the 
recommended dietary allowance (RDA) of 75 mg/day for women (healthy controls were 
all female) (69).The diabetic group did not meet the RDA. The RDA for vitamin E is 15 
mg/day for adults and neither group met this recommendation (70).  
 
Although not presented in the tables, significant decreases were observed in the mean 
weight and BMI of our diabetic subjects. However these decreases were not supported by 
changes in dietary intake as determined by our analysis of the week one and week four 
dietary data. The BMI of the diabetic subjects was 35.30 ± 10.3 kg/m2 at baseline and 
34.81 ± 9.98 kg/m2 at week four of the study. The weight of the diabetic subjects was 
99.3 ± 29.1 kg at baseline and 98.05 ± 28.45 at the final visit. Though these changes were 
statistically significant they did not appear to be clinically relevant and were not likely 
related to POMx™ supplementation. Some of the participants began this study around 
the holidays and they may have decreased their intake of high fat food items as a result of 
New Year’s resolutions or dietary changes that typically occur after the holidays. Also, 
participants could have become more health conscious after being enrolled in our 
research study. The recording of dietary food intake and pomegranate supplementation 
may have motivated participants to begin exercising or making other dietary changes. 
However, subjects were encouraged to keep a detailed record of their food intake and not 
to make lifestyle changes such as increasing physical activity. Yet, information related to 
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physical activity was not obtained for the purpose of our pilot study. Overall, it seems 
that the changes in weight and BMI may have been more related to some unreported 
change in diet or lifestyle factors than the POMx™ supplementation.  
 
The primary objective of this study was to examine the effects of pomegranate 
polyphenol supplementation, in the form of a POMx™ capsule, on clinical variables 
(fasting blood glucose, blood pressure, waist circumference, and dyslipidemia [high TCs 
and/or high TGs or low HDL levels]) and on biomarkers of oxidative stress (ox-LDL and 
MDA and HNE) and inflammation (CRP) in subjects with abdominal adiposity and type 
2 diabetes versus healthy controls. 
 
The intervention using pomegranate polyphenol supplements (POMx™ capsules) was 
based on the fact that they contain the major antioxidant phytochemicals present in the 
pomegranate and provide a convenient alternative to pomegranate juice (54). 
Additionally, few studies have been performed to evaluate the safety and efficacy of 
pomegranate supplements in human subjects.  
Our null hypothesis was that: 
• Pomegranate polyphenol supplementation will not affect glucose, lipids, and 
biomarkers of oxidative stress and inflammation in subjects with type 2 diabetes 
and healthy controls. 
• Pomegranate polyphenol supplementation will not affect safety parameters, such 
as, liver, kidney, and thyroid function tests, and complete blood cell count, in 
subjects with type 2 diabetes and healthy controls. 
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Based on our results we reject the null hypothesis that pomegranate polyphenol 
supplementation will not affect glucose, lipids, and biomarkers of oxidative stress and 
inflammation in subjects with type 2 diabetes and healthy controls because the 
biomarkers of lipid peroxidation, MDA and HNE were significantly decreased in subjects 
with type 2 diabetes. We fail to reject the null hypothesis that pomegranate polyphenol 
supplementation will not affect safety parameters, such as, liver, kidney, and thyroid 
function tests, and complete blood cell count, in subjects with type 2 diabetes and healthy 
controls. All safety parameters were within the normal range for healthy adults after the 
four week supplementation period, despite the significant increase.  
  
Certain limitations of our study need to be taken into consideration. This was a non-
randomized clinical pilot study with a convenience sample and a pre- and post- test 
intervention. Use of a convenience sample recruited at one site limits generalizability of 
the study results. Thus our results need further confirmation in larger placebo-controlled 
trials. This pilot study was non-randomized, thus in future studies a randomized crossover 
trial design would be beneficial as such a design reduces the influence of confounding 
variables with each subject serving as their own control. Use of a placebo capsule is also 
recommended in future research to ensure that positive findings are actually the result of 
the POMx™ capsule and not the “placebo effect.”  
 
Other caveats include the nature of the intervention and human subject compliance. 
Fresh, whole pomegranates are expensive as are the POMx™ capsules and pomegranate 
juice ($ 29.95 = 1month supply, Pom Wonderful LLC, Los Angelos, CA), thus limiting 
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their usefulness as a preventative/therapeutic measure by the general public. Also, human 
compliance was difficult to determine in this study. Participants were not closely 
monitored for compliance to supplement intake or accurate completion of dietary food 
records. In the future, the subjects should be more closely monitored to determine 
compliance to the therapy and to assess the validity of the food records, especially in 
terms of what is known about underreporting and inaccuracies in self-reported dietary 
assessment. It may also be beneficial to include more extensive food records, have 
participants complete food records for every week of the study, and also to include a pre-
intervention food frequency questionnaire (FFQ) that includes flavonoid food products to 
examine the amount/type of polyphenolic compounds typically consumed by the 
participants. Additionally, a 24-hour urine analysis would be useful in assessing 
compliance by detecting polyphenolic urinary metabolites. It may also be beneficial to 
measure levels of ellagic acid or total polyphenols in the plasma of the participants.  
 
Future studies should also include a more comprehensive analysis of biomarkers of 
oxidative stress and inflammation, such as, advanced glycation end products (AGEs) or 
F2-isoprostanes, as these markers are also elevated in patients with type 2 diabetes. 
Additionally, the four week trial phase may not be long enough to assess changes 
accurately in the selected biomarkers. In the future, a clinical trial of a longer duration 
should be implemented to assess the effects of long-term supplementation. Furthermore, 
oxidative stress and pro-inflammatory responses may be affected by a variety of stimuli 
including stress, increased activity, a high-fat diet, or bacterial infection (59,71). Thus it 
may be difficult to determine whether the selected markers, such as CRP, were elevated 
as a result of diabetes versus some other stimuli. Although, CRP values have been 
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reported to be a strong predictor in cardiovascular disease, it is important to note that 
consensus has not been reached on the usefulness/specificity of CRP as a predictive 
biomarker of diabetes. Thus in future studies it may be beneficial to assess additional 
biomarkers of inflammation to verify the results obtained from the CRP analysis. Such 
biomarkers could include interleukin-6 (IL-6) or tumor necrosis factor (TNF-α). 
 
Though somewhat expensive, the capsules are commercially available thus providing an 
alternative therapy to prevent diabetic complications. Due to the fact that most 
individuals in the United States do not consume the recommended servings of fruits and 
vegetables each day, it may be advised that the general population increase their intake of 
all fruits and vegetables and include whole fresh pomegranates and pomegranate juice as 
part of a healthful diet. Increased consumption of functional foods rich in natural 
polyphenols may be effective in reducing the oxidative stress and inflammation 
associated with diabetes which can lead to life-threatening cardiovascular disease 
complications.  
 
The use of dietary supplements among adults in the United States has increased since the 
early 1970’s when the National Health and Nutrition Examination Survey (NHANES I) 
reported that 27.5% of males and 37.9% of females used dietary supplements (72). 
Prevalence of supplement intake is now closer to 47.1% in males and 56.7% in females, 
according to data from NHANES 1999-2000. Over the past decade sales of dietary 
supplements has increased. In 2003, sales of dietary supplements reached approximately 
18.8 billion dollars. Therefore, further studies are needed to address the safety and 
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efficacy of supplements in healthy individuals as well as those with chronic diseases such 
as type 2 diabetes. Our pilot study addresses this gap by assessing a supplement that is 
relatively new in the market, though results warrant further investigation in larger 
controlled studies.  
 
In conclusion, this pilot study demonstrates the safety of the POMx™ capsules in both 
healthy controls and subjects with type 2 diabetes, and their efficacy in reducing lipid 
peroxidation in type 2 diabetics. However, future studies should be conducted to confirm 
the effects of these pomegranate polyphenol supplements on biomarkers of oxidative 
stress and inflammation in humans. 
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